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G PROTEIN-COUPLED ESTROGEN RECEPTOR REGULATION OF MIGRATION
AND METASTASIS IN THE BREAST

by

Sara Nicole Alcon

B.S. Biochemistry, Oklahoma Christian University, 2007

ABSTRACT

Proliferation and migration are critical steps within normal mammary
development and breast cancer progression. While 17β-estradiol (E2) stimulates
proliferation in normal and breast cancer cells through estrogen receptor-α (ERα) and G
Protein-Coupled Estrogen Receptor-1 (GPER) [1-3], GPER regulation of E2-dependent
migration has not been fully examined. GPER upregulates pathways necessary for
increased migration, including vimentin, matrix metalloproteinase-9, and mitogen
activated protein kinase (MAPK) signaling [1, 4-6]. GPER may also increase phosphofocal adhesion kinase (p-FAK) through Src activation [7, 8]. As a tumor develops, it
produces transforming growth factor-β (TGF-β) to activate normal fibroblasts in the
stroma, transforming them into cancer-associated fibroblasts (CAFs) and resulting in
increased metastasis. As metastasis is the primary cause of cancer-related death, it is
critical to examine how CAF activation is regulated [9-11]. GPER upregulates connective
tissue growth factor, an enhancer of TGF-β-induced fibroblast activation, and is
viii

correlated with increased breast cancer metastasis [12-14], suggesting a role for GPER in
fibroblast activation and metastasis.
In this study, GPER activation increased MCF10A breast epithelial cell migration.
Concomitant with GPER-dependent migration, increased expression of proteins
supporting collective migration was observed, including vimentin, p-FAK, E-cadherin,
and β-catenin, without increased proliferation. GPER inhibited PyMT breast cancer cell
individual migration. Additionally, GPER increased normal fibroblast activation and
proliferation in an EGFR-ERK-dependent manner but inhibited migration in vitro. In
vivo, the absence of GPER expression in fibroblasts increased tumor metastasis and
metastatic lesions size but did not affect collagen production. This is the first study to
demonstrate a role for GPER in migration of normal breast epithelial cells, activation of
normal fibroblasts, and the inhibition of tumor metastasis.
Separately, the role of GPER in the classical uterine responses to estrogen
activity, proliferation and water imbibition, traditionally attributed to ERα activation, was
examined. G-1, a GPER-selective ligand, stimulated lumenal epithelial cell proliferation
but not imbibition. AB-1, an ERα- and ERβ-selective ligand that activates genomic
responses but not rapid signaling, stimulated proliferation and imbibition. However, rapid
signaling is required for complete imbibition as AB-1 only induced ~60% of the E2induced imbibition.
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CHAPTER 1

INTRODUCTION

1

1.1 Estrogen
Estrogen, the primary female sex hormone, is the best characterized member of
the steroid hormone family that includes progestins, androgens, glucocorticoids, and
mineralocorticoids. There are three primary estrogens produced by the human body,
estrone (E1), estradiol (E2), and estriol (E3) (Figure 1.1). E1 is produced principally
outside of the ovaries by adipocytes and is responsible for most of the estrogenic effects
in postmenopausal women [15]. Throughout pregnancy, E3 produced by the placenta
becomes the dominant estrogen [16]. While both the 17α- and 17β-estradiol isoforms of
E2 are produced, 17β-estradiol, designated E2 throughout this study, is more
physiologically active. In the adult, non-pregnant, premenopausal female, E2 is the most
potent estrogen [17] with a wide range of physiologic effects, including maturation of the
reproductive and mammary tissues, maintenance of bone density [18], and immune
system modulation [19], as well as neuro- and cardioprotection [20, 21]. E2 is also
important in male fertility with effects on testicular and sperm development [22-24].
While E1 and E3 are predominantly produced by adipocytes and the placenta,
respectively, E2 is predominately produced in the ovarian follicle, although local
synthesis does occur in low amounts in adipocytes, liver, adrenal gland, bone, vascular
endothelium, and brain tissue [25-27]. Within the ovarian follicle, theca interna and
granulosa cells are regulated by the gonadotropins luteinizing hormone (LH) and folliclestimulating hormone (FSH) to initiate the multi-step process of converting cholesterol
into E2. Regulating the synthesis of gonadotropins, the hypothalamus releases nocturnal
pulses of gonadotropin releasing hormone (GnRH) that bind to the GnRH receptors on
gonadotrope cells within the anterior pituitary gland to stimulate production and secretion
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of LH and FSH [28] (Figure 1.2 A). LH then binds to the LH receptors present on the
theca interna cells in the ovary, triggering the conversion of cholesterol into progesterone
(P4) and, subsequently, to the androgens androstenedione or testosterone. FSH can also
stimulate the production of P4 within the granulosa cells; however, granulosa cells are
incapable of converting P4 into androgen due to the lack of 17β-hydroxysteroid
dehydrogenase. Any P4 produced within the granulosa cells must be transported to the
theca interna cells to be converted to androgen. Because theca interna cells do not express
aromatase, the p450 enzyme required to convert androgen into E2, the androgen must be
transported to the granulosa cells where the final aromatization can occur [29] (Figure 1.2
B). The E2 is then released into the serum and disseminated throughout the body. High
E2 serum levels inhibit hypothalamic secretion of GnRH, thereby forming a negative
feedback loop and the basis for the oscillatory nature of estrogen production and
menstrual cycle [28].

3

Figure 1.1 Physiologic estrogens. Chemical structures of the three naturally occurring
estrogens.
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A

B

Figure 1.2 E2 synthesis. A) The hypothalamus releases gonadotropin releasing
hormone (GnRH) inducing the anterior pituitary gland to produce luteinizing hormone
(LH) and follicle stimulating hormone (FSH). LH and FSH stimulate the ovarian
production of E2. High E2 levels inhibit GnRH. B) LH binds LH receptors on ovarian
theca interna cells, converting cholesterol into progesterone into androgens
androstenedione or testosterone through 17β-hydroxysteroid dehydrogenase (17βHSD). FSH binds FSH receptors on ovarian granulosa cells, producing progesterone.
Progesterone produced in the granulosa cells must be transported to theca interna cells
and converted to androgen. Androgen must be transported to granulosa cells where
FSH increases aromatase conversion of androgen into E2.

5

1.2 Classical Estrogen Receptors
While E2 was first isolated in 1930 [30], it was several decades before estrogen
receptor-α (ERα) was characterized in 1973 as a receptor responsible for estrogendependent signaling [31]. Following the development and analysis of a mice with a
targeted deletion of the ERα gene in 1993 [32], it became apparent ERα was not solely
responsible for all estrogenic effects, as some E2-dependent effects persisted, and a
second estrogen receptor, ERβ, was discovered shortly thereafter in 1996 [33].
ERα (ESR1) and ERβ (ESR2) are members of the highly conserved nuclear
receptor family of transcription factors. ERα and ERβ both contain six structural
domains: A/B, C, D, E, and F. The central C domain is comprised of two zinc fingers
responsible for DNA binding and is the most highly conserved domain with 95%
sequence homology between ERα and ERβ. This allows for both receptors to bind to the
same cis-acting hormone response elements (HREs), termed estrogen response elements
(EREs), located within the promoter regions of target genes [34]. While the C domains of
ERα and ERβ are highly conserved, variability within the NH2-terminal, A domain
allows for the recruitment of diverse co-regulatory proteins and transcription factors. This
leads to distinct, non-redundant roles for the two receptors, particularly within the
immune, skeletal, cardiovascular and central nervous systems [35-37]. The A/B domain
also contains the constitutively active activation function-1 (AF-1). A second activation
function (AF-2) and the ligand-binding domain (LBD) are located within the E domain.
Sixty percent sequence homology between the two receptors within the E domain results
in similar binding affinities for E2 (Kd = 0.05 – 0.1nM) [34, 38] (Figure 1.3 A).
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1.2.1 Classical Estrogen Receptor Signaling
Due to its small, lipophilic structure, estrogen passively crosses the cellular and
nuclear membranes to bind to the predominantly nuclear localized estrogen receptors. E2
binding to the LBD induces a conformational change, leading to the release of inhibitory
heat shock protein 90 (HSP90) chaperones from the D domain and the dimerization of the
receptor along the LBD. ERα and ERβ are transcriptionally active in both homo- and α/β
heterodimerized conformations due to homology within the DNA binding domain (DBD)
and LBD of the ERs [39]. The dimerized receptor then binds to the ERE present within
the promoter sequence of the target gene and regulates transcription, either positively or
negatively depending upon the recruited cofactors. As ERα and ERβ are members of the
nuclear receptor family of transcription factors, the ERE contains two half-sites with the
sequence RGGTCA, separated by three base pairs [39]. The ER dimer may also alter
transcription of non-ERE containing genes through association with the AP-1 or SP-1
transcription factors and their associated binding sites [40, 41]. Additionally,
phosphorylation by MAPK of Ser118 within the AF-1 region of ERα leads to ligandindependent transcriptional activation of estrogen-responsive genes [42] (Figure 1.3 B).
Apart from the long-term genomic responses induced by transcriptional
activation, ERα and ERβ also effect rapid signaling, non-genomic cellular responses, as
quickly as a few seconds after ligand binding. While the genomic effects are enacted
through nuclear localized ER functioning as a transcription factor, many of the nongenomic effects occur through palmitoylated, and thus membrane associated, ERα
(mERα) [43]. These rapid signaling effects include the production of phospholipase C
and cAMP leading to the influx of Ca2+ and associated downstream signaling, the release
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of nitric oxide within the vascular endothelial cells resulting in vasodilation, and the
activation of Src and thereby the PI3K and MAPK pathways [43, 44] (Figure 1.3 B).
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A

B

Figure 1.3 ER structure and signaling. A) ERα and ERβ contain six domains. The
A/B domain contains activation function-1 (AF-1) and recruits cofactors. The C
domain contains the DNA binding domain (DBD). AF-2 and the ligand-binding
domain (LBD) are in the E domain. B) E2 crosses the membranes to bind ER inducing
a conformational change and releasing of the inhibitory heat shock protein 90
(HSP90) chaperones. ER dimerizes along the LBD and binds to the estrogen response
element (ERE) or recruits transcription factors (TF) to regulate transcription. MAPK
phosphorylates ERα, inducing ligand-independent transcription.
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1.3 G Protein-Coupled Estrogen Receptor 1
In addition to the classical estrogen receptors, ERα and ERβ, a third estrogen
receptor, the G Protein-Coupled Estrogen Receptor 1 (GPER), has been identified. Unlike
the classical receptors, GPER is a member of the G protein-coupled receptor (GPCR)
superfamily and, as such, does not act directly as a transcription factor. GPER was first
cloned in the late 1990’s and named GPR30, designating it as an orphan seventransmembrane (7TM) GPCR [45-48]. Previously demonstrated to play a role in estrogen
signaling [1, 49], GPR30 was characterized as an independent estrogen receptor in 2005
and renamed GPER [50, 51].
1.3.1 GPER Signaling
GPER is the only known GPCR with a steroid ligand identified in vertebrates
[52]. Unlike other known GPCRs, GPER was determined to localize primarily on the
endoplasmic reticulum with possible rapid cycling to the plasma membrane [53, 54].
GPER binds E2 with a slightly weaker binding affinity (Kd = 3 - 6.6nM) than the
classical ERs (Kd = 0.05 - 0.1nM); however, it remains within the physiological range
[55].
As a GPCR, GPER associates with the heterotrimeric G proteins, Gαs and Gβγ
[50, 51]. E2 activation of GPER induces a conformational change in the Gα subunit
allowing for the exchange of the inactive bound GDP for GTP [56]. Following
dissociation from the Gβγ subunit and GPER, Gαs then activates adenylyl cyclase and
cAMP, leading to calcium-dependent signaling [49, 51]. Meanwhile, the Gβγ subunit
activates Src, leading to the activation of matrix metalloproteinases (MMPs) to cleave
heparin-bound epidermal growth factor (HB-EGF) and subsequent transactivation of the
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epidermal growth factor receptor (EGFR) and the mitogen activated protein kinase
(MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling pathways [1]. Activation of
the MAPK cascade and transcription factors, such as Elk-1 and serum response factor
(SRF), induce proliferation through the upregulation of c-fos, Bcl-2, cyclin D1,
connective tissue growth factor (CTGF), and early growth response 1 (Egr1), among
others [13] (Figure 1.4). GPER signaling through Src also leads to the development of
SHC-integrin α5β1 complexes, structures critical for fibronectin matrix assembly and
cellular movement and migration [57]. Additionally, GPER may induce cellular effects
independent of G proteins. Following ligand binding, GPER is phosphorylated by GPCR
kinase, leading to the recruitment of β-arrestin2 [58]. In most other GPCRs, β-arrestins,
once recruited to a ligand-bound receptor, act as an adaptor protein, scaffolding large
complexes of intracellular signaling molecules, such as Src, ERK1/2, PI3K, and NFκB
[59, 60]. Thus, it may be possible for GPER, through β-arrestin2, to directly activate the
MAPK and other kinase cascades to induce proliferation rather than relying on G protein
signaling alone.
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Figure 1.4 GPER signaling. E2 binds GPER and releases Gαs which activates adenylyl
cyclase and cAMP resulting in calcium flux. The Gβγ subunit activates Src. Src activates
matrix metalloproteinases (MMPs) to cleave heparin-bound epidermal growth factor
(HB-EGF) and transactivates epidermal growth factor receptor (EGFR). EGFR
stimulates the mitogen activated protein kinase (MAPK) and phosphatidylinositol 3kinase (PI3K) signaling and transcription.
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1.3.2 Selective Ligands
Because ERα, ERβ, and GPER are often co-expressed, are activated by the same
endogenous ligand E2, and share many signaling pathways, it is critical, but challenging,
to ascertain the precise role of each individual receptor. This can be accomplished by
manipulating the receptor expression levels, either by deleting a receptor or by examining
each receptor in a system or cell type expressing only that receptor. However, it is also
important to examine the activation or inhibition of each receptor in the presence of the
other two to determine possible interactions. This can be achieved through the
development of synthetic, selective ligands. A synthetic, GPER-selective agonist, G-1,
was identified from a library of 10,000 molecules and well characterized (Figure 1.5 A).
A substituted dihydroquinoline, G-1 selectively inhibits the binding of E2 to GPER while
showing no inhibition of E2 binding to ERα or ERβ. G-1 activates intracellular calcium
signaling and PI3K pathway in a GPER-dependent manner. No ERα- or ERβ-dependent
effects, either genomic or rapid signaling, were apparent in response to G-1 [53].
Additionally, two GPER-selective antagonists, G15 and G36, have been developed based
upon the GPER-selective G-1 scaffold (Figure 1.5 A). Because G15, the first antagonist
identified, weakly inhibits ERα at concentrations greater than 10μM, the highly selective
G36 was developed, exhibiting no inhibition of ERα or ERβ signaling [55, 61]. In the
initial screens, an agonist selective for ERα and ERβ, AB-1, was also identified (Figure
1.5 B). AB-1, a phenol-substituted oxabicyclo[3.3.1]nonene, is able to selectively bind
and activate ERα- and ERβ-dependent genomic effects, while exhibiting no activity
toward GPER [62, 63]. These selective ligands, together with targeted gene deletion,
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allow the individual roles of ERα, ERβ, and GPER to be unraveled both in vitro and in
vivo.
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A

B

Figure 1.5 Selective ligands. A) Chemical structures of GPER‐selective agonist G‐1
and antagonists G15 and G36. B) Chemical structure of ERα- and ERβ-selective
agonist AB-1.
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1.4 Estrogen in Uterine Physiology
The uterus is comprised of three primary layers, the outer muscular myometrium,
the basal layer of the endometrium, and the functional layer of the endometrium lining
the lumen of the uterus. In the adult, non-pregnant, pre-menopausal female, the menstrual
cycle induced by cyclic ovarian E2 production results in a biphasic uterine physiology.
The follicular, or proliferative, phase is characterized by proliferation of epithelial cells in
the functional layer of the endometrium as E2 levels increase to a maximal level at
ovulation. Following ovulation, E2 levels decrease precipitously due to the negative
GnRH feedback loop. During the luteal, or secretory, phase, progesterone (P4) levels
increase, inducing the differentiation and proliferation of stromal cells to transform the
endometrium into a receptive environment for implantation. In the absence of
implantation, the functional layer is shed as P4 levels decrease [64].
1.4.1 Estrogen Receptor Expression and Function in Normal Uterus
ERα, ERβ, and GPER are all expressed in each of the three uterine layers;
however, the expression levels of each receptor vary throughout the menstrual cycle.
Within the human endometrium, ERα protein levels greatly increases during the
proliferative phase in both epithelial and stromal cells, then decreases during the
secretory phase [65, 66]. GPER mRNA expression also increases during the proliferative
phase, particularly within the epithelial cells. However, while the mRNA levels decrease
during the secretory phase, the GPER protein levels remain constant [67]. ERβ protein
levels in the endometrium remain constant throughout the cycle [66]. Within the human
myometrium, ERα mRNA is expressed to a much higher level than ERβ mRNA,
although ERβ mRNA expression becomes dominant during pregnancy and post-
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menopause [68, 69]. Expression of estrogen receptors is also dynamic in the
postmenopausal human endometrium, as ERα protein levels decrease throughout the
endometrium and GPER localization shifts from the epithelium to primarily within the
stromal cells [70, 71]. Aromatase is also produced within the endometrial stromal cells,
allowing for increased levels of local E2 aromatization [72].
E2 has long been known to induce proliferation and edema, or water imbibition,
within the endometrial epithelial cells [73, 74]. These responses have become classical
estrogen responses within the uterus [74]. Through the use of mice lacking ERα and ERβ
through genetic deletion (knockout (KO)), the role of each of these receptors has been
clarified. Although both receptors are required for normal male and female fertility, as
ERαKO mice are sterile and ERβKO mice are either infertile or subfertile, their cellular
effects are quite distinct [32, 75]. ERαKO uteri are hypoplastic and exhibit half of the
normal wet weight, a measure of water imbibition [32]. While there is no change in wet
weight compared to wild type mice, ERβKO mice develop endometrial hyperplasia and a
decreased level of epithelial cell differentiation [75]. Taken together, it becomes clear E2
stimulation of ERα increases both epithelial cell proliferation and uterine wet weight.
ERβ appears to play a regulatory role, dampening ERα-induced proliferation, consistent
with anti-proliferative findings in vitro [76]. Although proliferation occurs in the lumenal
epithelial cells of the endometrium, E2 activates ERα receptors localized within adjacent
stromal cells, triggering epithelial proliferation through a paracrine response independent
of ERα epithelial expression [77, 78]. The role of GPER in these classical estrogenic
uterine responses has yet to be determined.
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1.4.2 Estrogen Receptor and Function in Endometrial Cancer
Endometrial cancer is the most common gynecologic malignancy with 49,560
estimated new cases and 8,190 deaths in the US in 2013 [79]. The primary risk factor for
development of endometrial cancer is prolonged exposure to estrogen, particularly
estrogen unopposed by P4 [80]. Additionally, women receiving the selective estrogen
receptor modulator (SERM) tamoxifen (TAM) for treatment of breast cancer are at an
increased risk of developing endometrial cancer [81]. Because TAM is a SERM, it acts as
an ER agonist in some tissues and an antagonist in other. In vitro, TAM induces
proliferation in numerous endometrial cancer cell lines [82, 83]. TAM targets the AF-2
domain of ERα and ERβ, sterically hindering the binding of E2 within the LBD, and
preventing the ensuing conformational change within the receptor. In tissues such as the
breast, where ligand-dependent AF-2 activity is dominant, TAM serves as an ERα
antagonist and is one of the recommended therapeutic for ERα positive breast cancer [84,
85]. In endometrial tissue, however, ligand-independent AF-1 activity and recruitment of
coregulatory proteins is more prevalent, and TAM serves as an ERα agonist [86]. TAM
has also been shown in vitro to act as a GPER agonist in both endometrial and breast
cells [50, 87].
Estrogen receptor expression has been correlated with endometrial cancer stage
and prognosis. In stage I/II tumors, indicating the tumor has not yet invaded beyond the
body of the uterus and cervix, high ERα expression is indicative of a good prognosis.
Decreased ERα expression levels are correlated with markers of poor outcome, such as
aggressive histological subtypes, adnexal spread, and recurrence, regardless of tumor
stage [88]. ERβ expression was not correlative with outcome in early stage tumors [89].
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Expression of both ERα and ERβ, however, is decreased in higher grade and advanced
stage endometrial cancer associated with myometrial invasion and de-differentiation [90].
Contrary to ERα, high GPER expression levels correlate with markers of poor prognosis,
such as high grade, advanced stage, cervical involvement, and aggressive histology, as
well as an overall lower survival rate. This correlation becomes more pronounced with
high-grade III/IV tumors, those that have spread beyond the uterus and cervix. In
addition, the expression of GPER inversely correlated with ERα expression levels [70].
In a positive feedback loop possibly leading to the progression of the tumor, TAM
stimulation can also increase GPER expression levels in vitro [91]. Despite this in vitro
and correlative data, very little is known concerning the role of GPER in both normal and
malignant endometria.

1.5 Estrogen in Breast Physiology
The mammary gland is unique as the majority of the organ development and
maturation occurs after birth during puberty. Within both male and female embryos,
thickening of the ventral skin develops by birth into a rudimentary ductal structure
supported by the surrounding mammary fat pad. The gland continues to grow in
proportion with the body until puberty [92]. At puberty, the ovaries begin their cyclic
production of E2, and additional development occurs within the female mammary gland.
The repetitive cycles of E2 signaling induces proliferation within the terminal end buds
(TEBs) resulting in the elongation and branching of the ductal structure throughout the
fat pad. During pregnancy, the final step for full maturation occurs as branching and
alveologenesis reach peak levels. In a fully developed, lactating mammary gland, the
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ducts are lined by a single layer of milk producing epithelial cells surrounded by
contractile myoepithelial cells to assist in milk ejection. Upon the cessation of lactation,
the ductal structure undergoes apoptotic remodeling known as involution [73].
1.5.1 Estrogen Receptors in Normal Breast Physiology
Once more, the roles of ERα and ERβ in mammary development have been
elucidated through the use of KO mice. While ERα, ERβ, and GPER are all expressed,
prepubertal development is independent of estrogen signaling as no defects are observed
in ERαKO, ERβKO, or GPERKO mice [35, 93]. However, ERαKO mice never develop
beyond the rudimentary structure present at birth [94]. The mechanism of this
developmental defect is complicated by multiple roles for ERα within the epithelial and
stromal compartments. One method of determining the role of these receptors in
individual components of the mammary gland is through the orthotopic transplant model.
Prior to the pubertal development, the epithelial duct structure is restricted to the
proximal end of the mammary fat pad and can be surgically removed. New epithelium is
then orthotopically transplanted, allowing it to grow in a physiologically relevant
environment [95, 96]. ERα is expressed in both the epithelial and stromal cells of the
developing mammary gland; however, ERα is heterogeneous, expressed in only 10-15%
of lumenal epithelial cells [2]. When ERαKO and ERα wild type (WT) mammary
epithelial cells (MEC) are mixed in vitro and transplanted into an ERαWT fat pad, only
the ERαKO cells proliferate, although they are unable to do so without the ERαWT MEC
co-transplantation [97]. Thus, consistent with previous findings, E2 activates ERα to
stimulate the proliferation of adjacent ERα negative cells [2]. This paracrine signaling is
believed to occur through ERα-induced cleavage of membrane bound amphiregulin by a
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disintegrin and metalloprotease (ADAM)-17. Amphiregulin then activates EGFR
signaling and proliferation on adjacent ERα negative cells [98]. In support of this,
amphiregulinKO and ADAM-17KO mice both show impaired ductal development [99].
In addition to the effects seen within the ERαKO epithelial cells, the ductal
defects may also be attributed to stromal cell impairment. To determine these stromal
effects, an ERαKO fat pad denuded of epithelia was orthotopically transplanted into the
fat pad of an ERαWT mouse. As the endogenous WT ducts grew, they avoided the KO
fat pad [97]. Without the pro-proliferative ERα stromal signals, the anti-proliferative
signals from the highly expressed stromal ERβ likely became dominant, inhibiting
elongation within the fat pad [100]. ERβKO mice exhibit delayed, but normal, branching
and ductal development [101]. The delay is likely caused by the irregularity of the estrous
cycle due to ovarian perturbation [102]. ERβKO mice have difficulty lactating due to a
lack of terminal epithelial cell differentiation. With the removal of the ERβ inhibitory
signal, the mammary gland becomes filled with cysts as the mice age, due to excessive
epithelial proliferation and minimal differentiation [101]. This data further demonstrates
the need to examine the cross-talk and interaction not only between the three estrogen
receptors, but also between the epithelial and stromal compartments of the breast.

1.6 Estrogen in Breast Cancer
Breast cancer is the most frequent form of cancer and second leading cause of
cancer-related deaths in women with an estimated 232,340 new cases diagnosed and
39,620 deaths in the US in 2013. It is estimated one in eight women will develop breast
cancer over the course of their lifetime [79]. Prolonged lifetime exposure to estrogen,
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through early menarche, late menopause, or hormone replacement therapy, increases the
risks of breast cancer, whereas the lack of cycling estrogen levels and induction of
epithelial differentiation during pregnancy and lactation is protective [103-106]. This
carcinogenic effect of estrogen exposure is primarily due to two mechanisms. First, E2
exposure has been shown to result in DNA adducts and mutations [107]. Second, DNA
repair systems are unable to clear these adducts and other damage incurred as E2
increases the proliferation rate of the epithelial cells, resulting in increased accumulation
of DNA mutations [108]. Evidence for the role of estrogen in breast cancer progression
first became apparent in the 1880’s. It was discovered that removal of the patient’s
ovaries resulted in the regression of the tumor [109]. However, not all tumors respond
similarly to estrogen. As a result, a complex breast cancer classification system has
arisen.
Upon a diagnosis of breast cancer, tumor samples are taken and tested for various
factors to determine stage, grade, and subtype. These factors combine to provide a
recommended treatment plan and prognosis. Breast cancer is staged according to size,
lymph node involvement, and distant metastasis [110]. The tumor is also graded based on
differentiation, defined as tubule formation or nuclear pleomorphism, and proliferative
activity, defined by the mitotic index [111]. While stage and grade of a tumor are good
indicators of the current level of tumor progression, they reveal very little about the
genetic profile of the tumor and thus about the response to treatment. For this reason,
additional histological markers are examined, the most important of which are the
expression levels of ER, progesterone receptor (PR), and human epidermal growth factor
receptor 2 (HER2), a member of the EGFR family with no known ligand [112]. Of all

22

breast cancers, 75-80% are initially ER and PR positive and hormone responsive,
allowing for the use of anti-estrogen and aromatase inhibitor (AI) treatment. HER2
overexpression occurs in 10-15% of breast cancer increasing the likelihood of either
homodimerization or dimerization with another member of the EGFR family and results
in the activation of the MAPK and PI3K signaling cascades. HER2 overexpressing
tumors are good candidates for the dimerization blocking anti-HER2 antibody
trastuzumab [113]. However, the remaining 10-15% does not express these three
receptors. Classified as triple negative breast cancer (TNBC), patients presenting with
these tumors have fewer treatment options [114]. Additional information is now available
to assist in characterizing tumors further through the increased implementation of a new
test, PAM50, which examines expression levels of 50 additional genes [115]. Taken
together, this diagnostic information has resulted in improved prognosis and outcome for
breast cancer patients [116].
1.6.1 Classical Estrogen Receptors in Breast Cancer
ERα is initially expressed in 75-80% of all breast cancer. Expression levels often
increase as low-grade ductal carcinoma in situ (DCIS) progresses to high-grade DCIS.
Once the tumor begins to invade the surrounding tissue, ERα expression decreases in
most tumors [117]. While it is thought E2 can induce tumorigenesis without ERα through
the induction of DNA adducts, long-term exposure to E2 fails to induce tumorigenesis in
ERαKO mice [118]. ERα proliferation signaling is likely a main cause for this protumorigenic role. Unlike the paracrine signaling mechanism found in normal mammary
epithelium, ERα positive breast cancer cells stimulate their own proliferation in a loosely
regulated manner [119]. ERα increases the expression of both myc and cyclin D1 to
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promote cell cycle progression. While this transcriptional regulation is also present in
normal mammary epithelial cells, ERα is able to induce these effects in breast cancer
cells more frequently and in a ligand-independent manner through increased activation
from overexpressed HER2. The interaction between HER2 and ERα also activates the
MAPK and PI3K cascades to stimulate additional proliferation [120]. ERβ continues to
regulate ERα-induced proliferation by inhibiting the transcription of cyclin D1, myc, p53,
p21, FOXO1, and other cell cycle regulators, thereby inducing G1 cell cycle arrest [121].
ERβ exhibits anti-tumorigenic effects by decreasing the levels of de-differentiation within
breast cancer cells, a hallmark of tumor progression. However, ERβ expression levels
often begin to decrease immediately in DCIS, preventing ERβ from inhibiting
proliferation and de-differentiation [122].
In addition to increasing proliferation, E2 also increases the metastatic abilities of
breast cancer cells. Metastasis is a multi-step process in which tumor cells develop a
motile phenotype, leave the primary tumor site by entering the blood or lymphatic
system, and circulate throughout the body to establish a secondary tumor site. Breast
cancer most often develops metastatic lesions within the lung, brain, and bone. E2
increases motility in breast, endometrial, and ovarian cancer cells in vitro [5, 123, 124].
One method by which ERα may increase migration is through E2 activation of protein
arginine N-methyltransferase 1 (PRMT1). PRMT1 transiently methylates ERα which
allows ERα to form a cytoplasmic complex with PI3K, SRC, and focal adhesion kinase
(FAK). The increased focal adhesion turnover results in increased migration [125].
Because of the pro-tumorigenic role of ERα, several antagonists were developed
as breast cancer therapies, the most effective of which was TAM. Unlike in the
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endometrium, TAM functions as an effective ERα antagonist in breast cancer cells. In
premenopausal women with ERα positive breast cancer, administration of TAM for five
years is the recommended first line of treatment [85]. However, 30-50% of ERα positive
patients with advanced disease do not respond to TAM. Of those patients that do respond,
TAM is not effective after 5 years of treatment due to acquired resistance [126].
Regardless of ERα status, TAM functions as a GPER agonist, and this agonism is thought
to be one way breast cancer cells acquire TAM resistance [127].
1.6.2 GPER in Breast Cancer
While the role of GPER in normal mammary biology is relatively understudied,
GPER has been repeatedly demonstrated to play a significant role in breast cancer. In 321
breast cancer cases, 60% expressed GPER at or above levels found in normal breast
tissue. 40% of the tumors co-expressed GPER and ERα, and, interestingly, of the 122
ERα negative tumors, half expressed GPER. This high GPER expression correlated with
increased tumor size, HER2 overexpression, and increased metastasis [14]. This contrasts
with the inverse correlation of ERα expression levels with each of these variables [128].
However, in a separate study, loss of GPER expression correlated with increased breast
cancer metastasis [129]. It is important to note that in all of these studies, the expression
of GPER was assessed in the tumor cells only, not in the surrounding microenvironment.
Additionally, GPER positive patients treated with TAM had higher GPER expression
levels and a lower relapse free survival rate than those either not treated with TAM or
treated with AI [130].
Similar to ERα, GPER can exert pro-tumorigenic effects through stimulation of
both proliferation and migration. First, GPER increases proliferation in both ERα positive
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and negative breast cancer cells in vitro [1, 3]. While much of this proliferation is
induced through the signaling mechanism previously described, alternative mechanisms
may also exist within the deregulated environment of the cancer cell. GPER expression
levels are increased by EGFR activation, particularly in ERα negative breast cancer cells,
allowing the tumors to remain estrogen-responsive in the absence of ERα [131]. This
overexpression correlates with EGFR and HER2 overexpression in 70% of breast tumors,
significantly increasing the level of EGFR transactivation and proliferative signaling
within the cell [130]. Second, several possible pathways for induction of migration have
recently been identified. Interaction between the insulin-like growth factor-1 receptor
(IGF-1R) and other GPCR family members, through their G proteins, has been shown to
result in migration of breast cancer cells in vitro [132]. This transactivation of the IGF-1R
has now also been verified to occur through GPER, resulting in the stimulation of both
proliferation and migration of ERα positive breast cancer cells [4]. Possibly the most
significant effect of GPER on tumor cell migration is through the upregulation of CTGF.
In a microarray study of GPER-regulated gene transcription, CTGF, a known migration
stimulant, had the highest induction [13]. GPER-dependent transcription of CTGF is
increased even further under the hypoxic conditions commonly found within a tumor
[133]. As a tumor grows, the existing vasculature becomes insufficient to fully support
the tumor, resulting in poorly oxygenated, or hypoxic, regions furthest from the
vasculature and the transcription of hypoxia-inducible factor (HIF)-1α. Among a vast
array of pro-tumorigenic effects, HIF-1α increases GPER expression levels, thereby
increasing CTGF levels [134]. This increased CTGF results in increased proliferation and
migration of breast cancer cells in vitro [13, 135]. However, within a tumor, the majority
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of CTGF is not produced by the tumor cells themselves, but by the nearby stromal
fibroblasts, suggesting an interesting role for GPER in the tumor-stroma signaling
interplay.
1.6.3 Breast Cancer Microenvironment
While extensive effort and research has been put forth to understand and target
tumor cells, focusing on the tumor alone misses the important contributions of the
microenvironment in promoting tumorigenesis. Although most tumor cells develop from
an epithelial origin, they receive significant regulation, either pro- or anti-tumorigenic,
from the surrounding stroma. The influence can be so strong that a debate has developed
as to whether the first carcinogenic signal originates in the epithelium, thereby activating
the stroma, or in the stroma, inducing transformation of the epithelium [136-138]. Thus it
is important to examine both the efferent signaling pathway, from the tumor cells to the
stroma, and the afferent pathway, from the stroma to the tumor cells. The stroma of the
mammary gland is distributed throughout the adipocytes of the fat pad and is quite
heterogeneous, containing fibroblasts, inflammatory and immune cells, and blood vessels
with pericytes, endothelial, and smooth muscle cells. The stroma plays a significant role
in both carcinogenesis and tumor progression. In the orthotopic transplant model
previously discussed, irradiation of the denuded mammary fat pad prior to transplantation
of new normal epithelium resulted in tumor development [139]. Once breast tumors have
developed, the presence of altered, or desmoplastic, extracellular matrix (ECM) is
indicative of a more aggressive tumor and worse prognosis [140]. Although the ECM is
composed of more than 300 different proteins, collagen, fibronectin, and tenascin-C are
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the most common ECM components in breast cancer and are produced primarily by
cancer-associated fibroblasts in the stroma [141].
Fibroblasts are the most common cell type within the stroma; however, most of
these fibroblasts are quiescent. When the surrounding tissue is wounded, these fibroblasts
become activated, transforming into α-smooth muscle actin (SMA) expressing
myofibroblasts that assist in the wound repair and tissue remodeling [142]. Cancer is a
chronic, highly inflammatory malignancy, resulting in many of the same fibroblast
activating signals found in wounds. As such, it is often referred to as “the wound that
never heals” [143]. These signals recruit surrounding fibroblasts and begin to activate
them. In the initial stages of tumor development, fibroblasts are anti-tumorigenic,
inhibiting the growth of the tumor via gap junctions [144]. As the tumor progresses, the
fibroblasts become pro-tumorigenic and are classified as cancer-associated fibroblasts
(CAFs) [145]. The presence of an elevated number of CAFs recruited to the tumor is a
marker of increased tumor size, metastasis, and poor prognosis [9, 10]. One mechanism
of CAF activation is through the transforming growth factor (TGF)-β signaling pathway.
Within the ECM, TGF-β forms a complex with CTGF through which CTGF increases the
affinity of TGF-β for its receptor and enhances the activation of the Smad signaling
cascade to induce activation. A positive feedback loop is established as TGF-β then
upregulates CTGF gene transcription [12]. In vitro evidence indicates increased
expression of CTGF may be sufficient to induce fibroblast activation [146], and since
GPER upregulates CTGF, these findings suggest GPER may stimulate fibroblast
activation.
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Once activated, CAFs begin remodeling and stiffening the tumor ECM by
decreasing production and degradation of the collagen IV found in normal mammary
microenvironment and increasing the secretion of collagens I and III, fibronectin, and
tenascin-C [141]. CAFs also produce lysyl oxidase that increases the covalent bonds
within collagen fibrils, further stiffening the ECM [147]. Several pro-tumorigenic effects
result from this compressed, desmoplastic ECM. The compressed ECM increases the
concentration of local soluble growth factors, thereby increasing tumor proliferation
[148]. It also leads to higher interstitial pressure within the tumor, preventing drug
diffusion, thereby minimizing therapeutic efficacy. In a mouse model of pancreatic
adenocarcinoma, pharmaceutical inhibition of CAFs resulted in lower interstitial pressure
and increased chemotherapeutic efficiency [149]. The desmoplastic ECM also provides a
better substrate for tumor cell migration. In a recent study, tumor cell migration was
shown to be dependent upon the desmoplastic ECM. It also demonstrated CAFs generate
force- and protease-mediated tracks in the ECM, allowing the metastasizing tumor cells
to follow behind [150]. These tracks have also been shown in vivo in the margins of
human breast cancer samples [151]. Once in the vasculature, CAFs protect the tumor
cells from cell death as a result of anoikis and immune surveillance. By metastasizing
with their own primary site CAFs, the tumor cells are more likely to successfully
establish a secondary, metastatic lesion. Presumably, the metastasizing CAFs begin
remodeling the secondary site ECM and creating a pro-tumorigenic environment more
quickly than newly recruited and activated secondary site fibroblasts [152]. GPER has
been shown, through increased CAF production of CTGF, to increase the proliferation
and migration of both CAFs and breast cancer cells in vitro [13, 153]. The ability of
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GPER to increase CTGF, a known fibroblast activator, combined with the pro-metastatic
effect of CAFs, suggests a role for GPER in the transformation of normal mammary
fibroblasts into CAFs, resulting in the increased tumor cell migration and metastasis
associated with high GPER expression.

1.7 Project Rationale
The impact of E2 on breast development and maturation, as well as in the
development and progression of breast cancer, has been well characterized. E2 increases
proliferation of normal breast epithelial and tumor cells. It also increases the motility of
tumor cells and fibroblasts. An important challenge is to elucidate the role of specific
estrogen receptors in these responses. ERα increases proliferation through the rapid
activation of MAPK and PI3K signaling cascades and the genomic upregulation of myc
and cyclin D1 transcription [39, 43]. More recently, it has become evident that GPERmediated E2 signaling likely plays an important but poorly characterized role in breast
cancer etiology. Unraveling the specific role of GPER will enhance our understanding of
breast cancer etiology, and will be particularly relevant for the study of tamoxifenresistant breast cancer and tamoxifen-induced endometrial cancer [91, 127, 130]. GPER
increases proliferation within tumor cells through the activation of the MAPK and PI3K
cascades [1, 51]. It also increases CTGF production by CAFs in vitro, a key signaling
molecule in the migration and metastasis of tumor cells [13]. This suggests an important
role for GPER in microenvironmental regulation of tumor progression, the understanding
of which is critical to improving treatment and survival of breast cancer patients.
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1.8 Hypothesis and Specific Aims
While the majority of estrogenic effects in the breast have been attributed to ERα,
recent studies provide strong evidence for a significant contribution of GPER to estrogendependent responses in both normal and tumor tissue. However, the molecular
mechanisms by which GPER mediates tumor progression, and the specific tissue targets
of GPER activity, remain unclear. The studies described herein were designed to address
some of these gaps.
Thus, we hypothesize activation of GPER induces breast epithelial cell migration
and fibroblast activation, thus increasing breast cancer metastasis.
SPECIFIC AIM 1: Determine the role of GPER activation on breast epithelial cell
and tumor cell migration in vitro.
1.1: Assess the effect of GPER activation on epithelial cell migration.
1.2: Determine the effect of GPER activation on breast tumor cell migration.
SPECIFIC AIM 2: Determine the role of GPER activation in fibroblast-dependent
breast cancer metastasis.
2.1: Assess the effect of GPER in fibroblast activation and function in vitro.
2.2: Assess the effect of GPER in fibroblast-dependent metastasis in vivo.
SPECIFIC AIM 3: Determine the role of GPER, ERα, and ERβ in normal
endometrium estrogenic responses.
2.1: Examine the effects of ERα and ERβ in normal endometrium in vivo using
selective compounds.
2.2: Examine the effect of GPER in normal endometrium in vivo using selective
compounds.
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CHAPTER 2

GPER REGULATES BREAST EPITHELIAL AND
CANCER CELL MIGRATION
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2.1 Abstract
Migration is a critical process in the development and progression of both normal
mammary ductal structures and breast cancer. While E2 regulation of cell motility has
been demonstrated repeatedly, the role of GPER in mediating E2-dependent migration in
both normal and cancer cells has not been fully examined. GPER is known to upregulate
pro-migratory MAPK and PI3K signaling pathways, increase vimentin, and increase the
production and activation of MMP-9, all necessary actions for increased migration [1, 46]. It has also been theorized GPER may increase p-FAK through activation of Src [7, 8].
However, GPER may also inhibit breast cancer cell migration [53]. In the present study,
GPER activation was demonstrated to increase collective migration within the nontumorigenic MCF10A breast epithelial cell line. Concomitant with GPER-dependent
migration, increased expression and activation of proteins supporting collective migration
was observed, including vimentin, p-FAK, E-cadherin, and β-catenin, without increased
proliferation. Conversely, GPER inhibited the individual migration of tumorigenic PyMT
breast cancer cells derived from a mouse breast cancer model.

2.2 Introduction
The development and maturation of the mammary gland beyond a rudimentary
structure begins at puberty and is dependent upon ovarian 17β-estradiol (E2) production.
The repetitive cycles of E2 production induces proliferation and migration within the
epithelial cells of the terminal end buds (TEBs) resulting in the elongation and branching
of the mammary ducts throughout the fat pad [73]. E2 induces proliferation in normal and
breast cancer cells through both the classical estrogen receptor ERα and the GPCR GPER
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[1-3] and inhibits proliferation through ERβ [76]. E2 also regulates the migration
necessary for elongation and branching. In collective migration, as exemplified in
branching morphogenesis, leading cells found in the TEB form actin- and vimentindependent membrane protrusions enriched with integrins and matrix metalloproteinases
(MMPs) [6, 154, 155]. Integrins are heterodimeric extracellular matrix (ECM) receptors
comprised of an α and β subunit. Depending upon the specific composition of the ECM,
any of twenty-four known integrin heterodimers may be expressed [156]. The primary
integrin found within migrating mammary epithelial cells is α5β1 due to the high
fibronectin content within the ECM of normal mammary gland [157]. Intracellularly,
integrin-ECM binding initiates the assembly of focal adhesions at the attachment site,
inducing the autophosphorylation of focal adhesion kinase (FAK). This phosphorylation
allows Src to bind, further phosphorylating and activating FAK. Activated FAK then
serves as a scaffold for pro-migratory downstream signaling cascades, recruiting Src,
MAPK, and PI3K [158]. Cell migration is accomplished through the formation of focal
adhesions along the leading edge of a cell and dissolution of adhesions along the trailing
edge. Without FAK and the downstream Src recruitment, focal adhesions would remain
adhered to the ECM, preventing migration [8]. In addition to migration, leading cells
must also proteolytically degrade the ECM through the production and activation of
MMPs to generate a migratory path through the basement membrane surrounding the
epithelial cells [159]. Because cell-cell contacts such as adherens and tight junctions
remain intact during this process, cells attached to the leading cells are passively pulled
along, resulting in the elongation of the mammary duct [154].
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E2 regulates this migration at multiple points throughout the process. Through
ERα, E2 activates Src thereby regulating the activation of FAK, the downstream promigratory MAPK and PI3K signaling, and the turnover of focal adhesions [7, 158]. As a
result, ERαKO mice exhibit no elongation or branching of ducts upon stimulation with
E2, never developing beyond the rudimentary structure present at birth [94].
The pro-migratory MAPK and PI3K pathways can also be initiated through
GPER transactivation of the EGFR and interaction with the insulin-like growth factor-1
receptor (IGF-1R) [1, 4]. GPER also increases migration through the upregulation of
vimentin within the leading cells and increased MMP-9 activity [5, 6]. Additionally, Src
can be activated by E2 in an ERα-independent, G protein-dependent manner and is
significantly elevated in tamoxifen-resistant breast cancer cells [7, 8]. Since Src is a
critical activator of FAK, this suggests a role for GPER in the regulation of migration
through Src and FAK.
The migration observed in ductal morphogenesis is mechanistically similar to the
process by which breast cancer cells metastasize. Metastasis is a five step process by
which cells 1) invade through the basal lamina into the surrounding tissue, 2) intravasate
into the blood or lymphatic vessels within the primary tumor site, 3) survive apoptosis
and immune surveillance while circulating through the vascular system, 4) extravasate
into the tissue of a secondary tumor site, and 5) establish a metastatic lesion. Breast
cancer most often develops metastatic lesions within the lung, brain, and bone, and the
presence of distant metastases elevates a breast cancer case to the most advanced stage
and worst predicted outcome [110].
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Metastasis of cancer cells has been observed to occur through two primary
methods: individual cell migration or collective migration. While both migration methods
are often detected, leukemia, lymphoma, and most solid stromal tumors seem to
preferentially metastasize through individual migration, and most epithelial tumors
appear to metastasize through collective migration [160, 161]. The mechanism for both
collective and individual tumor cell migration is nearly identical to branching
morphogenesis with integrin, MMP, and FAK involvement, although much more loosely
regulated than in normal breast development [161]. However, individual migration
requires the dissolution of cell-cell contacts, most notably the downregulation of Ecadherin. E-cadherin is a transmembrane protein that dimerizes with E-cadherin on
adjacent epithelial cells forming adherens junctions. E-cadherin is linked to the actin
cytoskeleton through β-catenin and assists in epithelial cell apical-basal polarization
[162]. Loss of E-cadherin and adherens junctions results in a loss of apical-basal cell
polarity and de-differentiation of epithelial tumor cells into a more motile, mesenchymal
phenotype, permitting individual tumor cells to migrate away from the main tumor mass.
Thus, decreased E-cadherin expression is a primary hallmark of tumor cells undergoing
the epithelial-to-mesenchymal transition (EMT) [160]. The loss of E-cadherin alone is
sufficient to induce migration and invasion, increasing metastasis [163]. High E-cadherin
expression levels are frequently found in ERα positive breast cancer since ERα decreases
expression levels of snail and slug, the primary transcriptional repressors of E-cadherin
[164, 165]. However, as ERα decreases with advanced tumor progression, expression of
E-cadherin is concomitantly reduced, increasing the probability of tumor metastasis
[163]. The loss of ERβ also leads to a decrease in E-cadherin expression, consistent with
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the role of ERβ in promoting differentiation [101, 166]. The loss of ERα and expression
of normal to high levels of GPER are both independently correlated with increased breast
cancer metastasis [14, 128], again suggesting a strong role for GPER in migration.
However, GPER may also inhibit breast cancer cell migration [53]. Indeed, in a separate
study, loss of GPER expression correlated with increased breast cancer metastasis [129].
It is not currently known under what conditions GPER may promote or inhibit migration.
In the present study, GPER activation is demonstrated to increase collective
migration within breast epithelial cells. This is confirmed by the upregulation of the
collective migration markers vimentin, p-FAK, E-cadherin, and β-catenin, as well as the
lack of increased proliferation. Conversely, GPER inhibits the individual migration of
breast cancer cells.

2.3 Methods
2.3.1 Cell lines and reagents. Immortalized, non-transformed, non-tumorigenic
MCF10A human breast epithelial cells (ATCC, Manassas, VA; catalog number CRL10317) were cultured in MCF10A complete media (DMEM/F-12 supplemented with 5%
horse serum, 10μg/mL insulin, 100ng/mL cholera toxin, 0.5μg/mL hydrocortisone,
20ng/mL recombinant epidermal growth factor (EGF) and 1% penicillin/streptomycin
(P/S)). PyMT breast cancer cells, a clonal immortalized, tumorigenic cell line, were
previously generated in the lab from the mammary tumors of a 7wk FVB/N-Tg(MMTVPyVT)634Mul/J (MMTV-PyMT) transgenic mouse, that overexpresses the polyoma
middle T antigen (PyMT) under the control of the mouse mammary tumor virus
(MMTV) promoter [167]. PyMT cells were maintained in epithelial cell medium
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(DMEM/F-12 supplemented with 5% fetal bovine serum (FBS), 10μg/mL insulin,
0.5μg/mL hydrocortisone, 10ng/mL EGF and 1% P/S). Cells were cultured in a
humidified atmosphere containing 5% CO2 at 37oC. Dulbecco’s Modified Eagle Medium
(DMEM)/F12, phenol red-free DMEM/F12, E2, FBS, NGS, horse serum, insulin, cholera
toxin, hydrocortisone were from Sigma. EGF and penicillin/streptomycin (P/S) were
from Invitrogen. G-1 was synthesized as described [53] and provided by Dr. Jeffrey
Arterburn (New Mexico State University).
2.3.2 Wound healing assay. Wound healing “scratch” assays were performed as
previously described [168]. Briefly, cells were passaged either into 24-well cell culture
plates or onto 12mm glass coverslips (Electron Microscopy Sciences, Hatfield, PA) for
immunostaining. Confluent cells were cultured in phenol red-free MCF10A media with
all supplements listed above for 24 hr, then washed and placed in starvation media
(phenol red-free DMEM/F-12 supplemented with 2% dextran-charcoal-stripped FBS,
10μg/mL insulin, 100ng/mL cholera toxin, 0.5μg/mL hydrocortisone, and 1% P/S) for
24hr to induce cell synchronization as previously described [169]. Following
synchronization, cells were pretreated for 24 hours with dimethylsulfoxide (DMSO)
vehicle control, E2 (10nM and 100nM), G-1 (10nM and 100nM), or EGF (10nM).
Following pretreatment, a 0.5cm wound was scratched into the center of the confluent
cells with a 2μL pipet tip with an average width of 200μm. The treatment media was
replaced to remove cell debris. The wound was imaged at four marked locations with a
Zeiss 35 Axiovert microscope using MetaMorph software at 0, 12, 15, 18, 21, and 24hr
post-wound. Migration was analyzed by measuring the total area for each wound using
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MetaMorph software. The area of the wound at each time point was expressed as the
percentage of the 0hr wound area remaining.
2.3.3 Electric cell-substrate impedance sensing (ECIS) wound healing assay. ECIS
migration assays were performed in the ECIS model Zθ (Applied Biophysics) as
previously described [170]. Briefly, PyMT cells were seeded into ECIS electrode arrays
(8W10E) (Applied Biophysics) in complete PyMT epithelial media. Confluent cells were
washed, placed in starvation media (phenol red-free DMEM/F-12 supplemented with
10μg/mL insulin, 0.5μg/mL hydrocortisone, and 1% P/S) for 24h, and pretreated with
DMSO vehicle control, E2 (100nM), G-1 (100nM), or EGF (10nM) in starvation media
for 48h. Treatment media was changed, and baseline impedance was measured in ECIS
normal mode (1μA at 4 kHz) at 5min intervals for 1hr. The monolayer was electrically
wounded with an elevated field pulse of 5mA at 60 kHz for 2min, resulting in a rapid
decrease in impedance. The increasing impedance indicative of migration was measured
in ECIS normal mode for 24hr. Impedance for each time point was normalized to the first
impedance measurement after wounding.
2.3.4 Transwell migration assay. MCF10A cells were placed in starvation media
described above for 24hr and pretreated for 48 hours in starvation media with DMSO
vehicle control, E2 (10nM and 100nM), G-1 (10nM and 100nM), or EGF (10nM). Cells
were resuspended and seeded into 8μm pore size Transwell inserts (Costar) in a 24-well
plate at 1 x 105 cells/well. Starvation media containing treatment was added to both the
upper and lower chamber and 10% c.s. FBS was added to the lower chamber as a
chemoattractant. After 48h of incubation at 37oC, non-migrated cells were removed from
the upper side of the membrane with cotton swabs, and the cells on the lower surface of
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the membrane were fixed in cold methanol on ice for 10min. Membranes were mounted
with Vectashield mounting medium with 4',6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories). Five random fields from each membrane were imaged with a Zeiss 200M
Axiovert microscope using MetaMorph software. The total number of cells for each
membrane were counted and normalized to the vehicle control.
PyMT migration assays were performed similarly. Cells were placed in starvation
media for 24hr. Cells were seeded into 8μm pore size Transwell inserts (Costar) in a
24-well plate at 2 x 104 cells/well. Starvation media containing DMSO vehicle control,
E2 (100nM), G-1 (100nM), or EGF (10nM) was added to both the upper and lower
chamber and 10% c.s. FBS was added to the lower chamber as a chemoattractant. Cells
were allowed to migrate for 24hr.
2.3.5 Immunostaining analysis. For immunostaining, cells were cultured on 12mm acidwashed, lysine coated, glass coverslips and fixed with 4% paraformaldehyde for 20 min
at 20oC. The cells were permeabilized with cold methanol for 10 min on ice and blocked
with 5% normal goat serum (NGS) diluted in phosphate-buffered saline (PBS) for 15 min
at 20oC. Cells were stained with primary antibody diluted in 5% NGS + PBS 1hr at 20 oC
in a humidified chamber followed by detection with secondary antibody for 1hr at 20 oC.
Coverslips were mounted on slides with Vectashield mounting medium with DAPI
(Vector Laboratories). Three random fields from each coverslip were imaged with a Zeiss
200M Axiovert microscope using MetaMorph software. Primary antibodies used were
rabbit anti-Ki-67 (Thermo Fisher), mouse anti-phospho-FAK (Y397) (BD Biosciences),
mouse anti-vimentin (3B4) (Millipore), mouse anti-E-cadherin (BD Biosciences), and
mouse anti-β-catenin (BD Biosciences). Secondary antibodies were anti-rabbit and anti-
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mouse IgG antibodies conjugated to Alexa 488 (Molecular Probes). Preliminary studies
examining vimentin, p-FAK, β-catenin, and E-cadherin are all n=1.
2.3.6 Statistics. Statistical analysis was performed using GraphPad Prism version 4.03.
Comparisons of results between different treatment groups were determined using a oneway Analysis of Variance (ANOVA) followed by a Bonferroni correction for multiple
comparisons as a post-hoc test. Data represents the mean ± SEM of three or more
separate experiments. P-values less than 0.05 were considered to be significant.

2.4 Results
2.4.1 GPER increases breast epithelial cell migration
Although E2 activation of GPER stimulates many pathways involved in
migration, such as increased MAPK and PI3K signaling, vimentin, and MMP production,
no studies have been performed to determine the effect of GPER on normal breast
epithelial cell migration required for proper breast development. In order to study such
effects, MCF10A cells were selected as an ideal in vitro model system. MCF10A cells
are immortalized, non-transformed human breast epithelial cells isolated from a reduction
mammoplasty and have many features of normal epithelial cells. Genetically, they exhibit
a near-diploid karyotype with minimal rearrangement. In vitro, these cells demonstrate
three-dimensional growth in collagen controlled by hormones and growth factors and an
inability to grow in anchorage-independent conditions. Finally, in vivo MCF10A cells are
non-tumorigenic and as such, when injected into immune compromised mice, no tumor
will develop [171]. In addition, MCF10A cells express only GPER, containing
insignificant levels of ERα or ERβ, allowing specific examination of the role of GPER
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activation by both the endogenous ligand, E2, and the synthetic, GPER-selective ligand,
G-1 [172].
Using MCF10A cells, a wound healing “scratch” assay was performed to
determine the role of GPER in normal breast epithelial migration. MCF10A cells were
seeded to confluency, starved of growth factors and E2, and pretreated for 48hr with E2
or G-1. The cells were wounded and migration was observed. G-1 and E2 both stimulated
significantly increased migration in a dose-dependent manner, as compared to the sham
control (Figure 2.1). At 100nM, G-1 activation of GPER induced a significant increase in
migration beginning at 12hr after the initial wounding with full wound closure by 18hr
(Figure 2.1 A). Likewise, 100nM E2 also significantly increased migration, though at a
slower rate than G-1, and did not achieve full wound closure by 24hr post-wound (Figure
2.1 B). As GPER is the only known estrogen receptor expressed within MCF10A cells,
this may indicate a differential GPER response to the two ligands. This functional
selectivity between two ligands binding the same GPCR and eliciting qualitatively
different outcomes has been previously reported [173]. Importantly, both ligands
significantly increased epithelial cell migration. Visual inspection indicated the cells did
not break off and migrate individually, instead migrating as a sheet to close the wound,
indicative of the collective migration seen in ductal morphogenesis.
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A

B

Figure 2.1 GPER increases breast epithelial cell migration. Wound healing scratch
assays were performed on MCF10A cells pretreated for 48hr with A) G-1 or B) E2.
The wound area was photographed at 0, 12, 15, 18, 21, and 24hr post-wound. Images
shown are 24hr post-wound. Migration was quantified as described in Methods.
*p < .05 compared to sham.
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2.4.2 GPER has no effect on proliferation in migrating epithelial cells
While the sheet-like movement induced by GPER activation is highly indicative
of collective migration, it is possible the cells were not migrating, but proliferating into
the wound, effectively closing the wound by increasing cell numbers. MCF10A cells
have previously been demonstrated to migrate collectively, independent of proliferation
[6]. However, because GPER is known to increase proliferation, it is important to
distinguish between the two responses as a cause of the wound closure. To do so,
MCF10A cells were grown on coverslips, and a wound healing assay was performed as
described above. Proliferation was analyzed through the immunodetection of Ki-67, a
nuclear protein present in all cells within any stage of the cell cycle except G0. Although
proliferating cells were detected, the proliferation was uniform throughout the monolayer,
and there was no difference in proliferation following treatment with E2 or G-1 as
compared to the sham control (Figure 2.2). This confirms the increased wound closure
induced by GPER activation is a result of increased cell migration.
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A

B

Figure 2.2 GPER has no effect on proliferation in migrating epithelial cells. A)
MCF10A cells treated with E2 or G-1 were immunostained to detect the
proliferation marker Ki-67 (green) and counterstained with DAPI nuclear stain
(blue) B) Quantitation of proliferation. Data is expressed as a percentage of total
cells positive for Ki-67 at the wound edge.
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2.4.3 GPER increases expression of proteins required for collective migration
Visual inspection of MCF10A cell migration in wound assays indicates a
collective migration phenotype (Fig. 2.1). To confirm this, preliminary studies were
performed measuring the expression of proteins induced during and required for
collective migration. Migratory MCF10A cells are known to increase vimentin
expression in a polarized manner along the leading edge of the cells, assisting in the
formation of membrane ruffles and protrusions necessary for migration. Vimentin
expression is not seen in cells away from the wound edge [6]. MCF10A cells treated with
E2 or G-1 increased vimentin along the wound edge, but not away from the wound, as
compared to the sham control (Figure 2.3). Vimentin was polarized to the leading edge of
the cell, in front of the nucleus, indicative of a migrating cell. Additionally, collective
migration necessitates an increase in cell-cell contacts, specifically adherens junctions.
GPER activation by both E2 and G-1 increases the level of E-cadherin within the
migrating cells along the wound edge as compared to the control (Figure 2.3). There was
no corresponding E-cadherin increase in the non-migratory cells distant from the wound.
To test the localization of this additional E-cadherin to the adherens junctions, β-catenin
protein levels and localization at the cell membrane was examined as a marker of fully
formed adherens junctions. The increase in E-cadherin and adherens junctions in GPERactivated migrating cells was confirmed by a concomitant increase in membrane
localized β-catenin (Figure 2.3). Finally, the expression level of phosphorylated FAK (pFAK) was examined. P-FAK is indicative of the formation and dissolution of focal
adhesions, a macromolecular complex necessary for migration linking the ECM with
intracellular signaling machinery through integrins [8]. GPER activation by both E2 and
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G-1 increased p-FAK expression, as compared to the sham control, in a pattern consistent
with localization to focal adhesions (Figure 2.3). Cumulatively, this data indicates GPER
activation does significantly increase collective migration of breast epithelial cells.
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Figure 2.3 GPER increases expression of proteins required for collective
migration. MCF10A cells were treated with E2 or G-1 and wounded. Cells were
stained for collective migration markers vimentin, E-cadherin, β-catenin, or p-FAK,
as indicated (green) and counterstained with DAPI nuclear stain (blue).
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2.4.4 GPER has no effect on individual migration in epithelial cells
To test the role of GPER activation on individual migration of breast epithelial
cells, MCF10A cells were again E2 and growth factor starved, pretreated for 48hr, and
seeded into the upper chamber of a Boyden chamber Transwell migration assay. A
chemoattractant, 10% c.s. FBS, was placed in the bottom chamber, and cells were
allowed to migrate for 48hr. In this assay, migrating cells must detach from surrounding
cells to migrate individually through the pores in the membrane [168]. Compared to the
sham control, no increased migration was detected following GPER activation by either
G-1 or E2 at any dose (Figure 2.4). Thus, GPER does not induce individual migration in
breast epithelial cells, consistent with the GPER-dependent increase in adherens junctions
previously observed.
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Figure 2.4 GPER has no effect on individual migration in epithelial cells.
Transwell migration assays were performed on MCF10A cells pretreated with E2 or
G-1 for 48hr. Cells were allowed to migrate for 24hr. Cells that migrated through the
membrane were counted and normalized to sham-treated controls. *p < .05 compared
to sham.
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2.4.5 GPER has no effect on combined individual and collective migration in breast
cancer cells
While GPER has now been shown to induce collective migration in breast
epithelial cells, the role of GPER in cancer cell migration is still unclear. GPER has been
shown to both increase and inhibit breast cancer cell migration [13, 53]. To further
examine the role of GPER in migration, a PyMT breast cancer cell line previously
isolated and cloned from the mammary tumors of an MMTV-PyMT mouse was selected.
Unlike MCF10A cells, PyMT cells express all three estrogen receptors, thus allowing any
interactions affecting migration to be examined. Initially, migration of PyMT cells was
assessed in a “scratch” wounding assay; however, in all treatment samples, a combination
of sheet-like migration and individual cell migration was observed (data not shown).
Because of the individually migrating cells, quantitation of migration was not possible.
Thus, the test was repeated using an electric cell-substrate impedance sensing (ECIS)
wound healing assay. This method allows for migration measurement based upon the
inherent electrical current impedance properties of cell membranes. PyMT cells were E2
and growth factor starved, pretreated for 48hr, and seeded into specially developed
chamber slides, containing 10 electrodes/chamber. In normal sensing mode, the ECIS
machine measures impedance by applying a low electrical current that does not impact
the cells [170]. A damaging current is then applied, disrupting cells directly over the
electrode, thereby creating a “wound” similar to that in the scratch assay. Immediately
following the wounding, there is a precipitous drop in impedance. Cells not directly over
the electrode are unharmed. The normal sensing mode then measures impedance levels
over time to determine the migration of cells over the electrode to cover the wound [170].
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GPER activation by G-1 and E2 did not increase PyMT breast cancer cell migration, as
compared to the sham control (Figure 2.5).
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Figure 2.5 GPER has no effect on combined individual and collective migration
in breast cancer cells. ECIS migration assays were performed on PyMT cells
pretreated with E2 or G-1 for 48hr. Impedance was measured for 16hr and normalized
to the first impedance measurement after wounding.
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2.4.6 GPER inhibits individual migration in breast cancer cells
Because the ECIS wound healing assay measures both collective and individual
migration indiscriminately and PyMT cell individual migration had been observed, a
Transwell migration assay was also performed to measure individual migration alone.
PyMT cells were E2 and growth factor starved and seeded into the upper chamber of a
Boyden chamber Transwell migration assay. A chemoattractant, 10% c.s. FBS, was
placed in the bottom chamber, and cells were allowed to migrate for 24hr. GPER
activation by both E2 and G-1 significantly inhibited the individual migration of PyMT
breast cancer cells as compared to the sham control (Figure 2.6). This result indicates
GPER activation does inhibit individual cell migration in this model.
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Figure 2.6 GPER inhibits individual migration in breast cancer cells. Transwell
migration assays were performed on PyMT cells treated with E2 or G-1. Cells were
allowed to migrate for 24hr. Cells that migrated through the membrane were counted
and normalized to sham-treated controls. *p < .05 compared to sham.
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2.5 Discussion
Migration is a critical process in the development and progression of both normal
mammary ductal structures and breast cancer. While E2 regulation of motility has been
demonstrated repeatedly, the role of GPER in mediating E2-dependent migration has not
been fully examined. GPER is known to upregulate pro-migratory MAPK and PI3K
signaling pathways, increase vimentin, and increase the production and activation of
MMP-9, all necessary actions for migration [1, 4-6]. It has also been theorized GPER
may increase p-FAK through activation of Src [7, 8]. However, GPER may also inhibit
breast cancer cell migration [53]. This is the first report of GPER inducing collective
normal breast epithelial cell migration while inhibiting individual breast cancer cell
migration.
GPER activation by both the endogenous ligand, E2, and the synthetic, selective
ligand, G-1, results in increased migration of the non-tumorigenic MCF10A breast
epithelial cell line (Figure 2.1). Because it was possible the cells were simply
proliferating to fill wound, rather than migrating into it, a proliferation assay was
performed. There was no difference in proliferation between GPER-activated and
control-treated cells (Figure 2.2). This result would seem to contradict previous reports of
GPER-induced breast epithelial cell proliferation [1]. However, GPER likely stimulates
both proliferation and migration primarily through activation of the MAPK pathway.
Previous reports demonstrate the MAPK cascade will not simultaneously induce both
proliferation and migration within the same cell as these two signals inhibit one another
through opposing regulation of cyclin D1 and thus the cell cycle [174, 175]. Within these
studies, additional signaling along the wound edge resulted in a migratory signal, while
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away from the wound edge proliferation occurred [175]. The lack of increased
proliferation within the monolayer distant from the wound in the current study is likely an
artifact of the experimental process, as the wound healing scratch assay requires a
confluent monolayer. Upon reaching confluency, MCF10A cells exhibit contact
inhibition and suppress proliferation [171]. Unlike in the confluent epithelial cells lining
the mammary ducts in vivo, the MCF10A cells in this experiment were grown directly on
tissue-culture treated plastic or glass and were not in contact with significant levels of
ECM. Confluent epithelial cells grown on ECM similar to that found in vivo exhibit a
lower threshold for growth factor concentration required to overcome the contact
inhibition [176]. The threshold may be lower due to integrin-ECM binding stimulating
additional activation of the MAPK pathway to induce proliferation [177]. This threshold
is lowered still further with a stiffer ECM composition [176]. This is consistent with
increased levels of the much stiffer collagen I surrounding the highly proliferative
terminal end buds in the developing mammary gland in vivo [178].
To further confirm migration, as well as determine the method of migration,
preliminary studies of several proteins required for collective migration were performed
(Figure 2.3). The first step in migration is the formation of membrane ruffles and
protrusions. These require coordinated remodeling of the actin and filamentous
cytoskeleton. Treatment of MCF10A cells with E2 or G-1 both resulted in increased
vimentin, polarized to the leading edge of the cell, indicative of migration. These
membrane protrusions are enriched with integrins to bind the ECM and form focal
adhesions. FAK is recruited to focal adhesions where it is autophosphorylated resulting in
the binding of Src, further activation, and focal adhesion turnover [158]. The coordinated
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formation of adhesions along the leading edge and dissolution along the trailing edge is
essential for cell migration. Concomitant with increased migration, GPER activation
results in increased p-FAK localized to the focal adhesions.
Characteristic of collective migration, GPER activation induced sheet-like
migration of the epithelial cells. In collective migration, migrating cells increase cell-cell
contacts, specifically adherens junctions, allowing the leading cells to pull the remainder
of the cells along. This migration is necessary for the ductal morphogenesis and
elongation occurring during mammary gland maturation [154]. Indeed, GPER activation
results in increased adherens junctions as evidenced by increased E-cadherin and βcatenin, confirming GPER stimulation of collective migration. Consistent with increased
cell-cell contacts, GPER activation does not result in increased individual migration
within epithelial cells (Figure 2.4).
GPER exhibits seemingly contradictory migratory effects in the PyMT breast
cancer cell line to those demonstrated in epithelial cells. Rather than stimulating
migration, GPER activation inhibits PyMT individual migration (Figure 2.6), while
having no effect on migration measured by ECIS (Figure 2.5). This inhibition may be due
to the presence of ERβ in PyMT cells. While MCF10A cells only express GPER, PyMT
cells express all three known estrogen receptors. In addition to its role in inhibiting
proliferation, ERβ has recently been shown to inhibit migration and invasion of breast
cancer cells as well [179, 180]. This inhibition can occur in a ligand-independent manner
through the phosphorylation of ERβ S105 by ERK1/2 [179]. Since GPER activation
increases ERK1/2 activation [1], it is possible GPER activation is inducing the
phosphorylation of ERβ S105, thereby inhibiting PyMT breast cancer cell migration.
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The role of ERβ S105 phosphorylation may also explain the lack of migration
inhibition observed by ECIS measurement. Because PyMT breast cancer cells do not
exhibit the contact inhibition present in epithelial cells and phosphorylated ERβ is unable
to inhibit proliferation in a ligand-independent manner [179], the PyMT cells may have
filled the wound over the electrode through GPER-induced proliferation. This would
negate the GPER migration inhibition demonstrated in the individual transwell migration
assay. This suggests a possible novel interaction between GPER and ERβ in the
regulation of breast cancer cell migration.
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CHAPTER 3

GPER REGULATION OF FIBROBLAST ACTIVATION
AND FUNCTION
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3.1 Abstract
As a breast tumor develops, the normal mammary fibroblasts in the surrounding
stroma are recruited and activated by the increased inflammatory cytokines, primarily
TGF-β, produced by the tumor, transforming into cancer-associated fibroblasts (CAFs).
The pro-tumorigenic role of activated CAFs in tumor growth and metastasis has been
recently characterized. The increased presence of CAFs within the tumor is correlated
with increased tumor size, metastasis, and poor prognosis [9, 10]. Since metastasis is the
primary cause of cancer-related death [11], it is critical to understand the mechanisms by
which normal fibroblasts become activated and transformed into CAFs. Stimulation of
GPER increases the production of connective tissue growth factor (CTGF), a significant
enhancer of TGF-β-induced fibroblast activation [12, 13]. Additionally, GPER
expression is correlated with increased breast cancer metastasis [14], suggesting a role for
GPER in fibroblast activation and subsequent tumor metastasis. This study demonstrates
GPER activation leads to increased normal mammary fibroblast activation and
proliferation in an EGFR-ERK-dependent manner. However, GPER fibroblast activation
did not result in increased migration as anticipated, but inhibited fibroblast migration in
vitro. This inhibition was consistent in vivo as the loss of GPER fibroblast expression
leads to increased tumor metastasis and larger metastatic lesions without increased
primary tumor size. This increased metastasis was not a result of altered ECM, as GPER
did not affect collagen production either in vitro or in vivo. This is the first study to
demonstrate a role for GPER in both the activation of normal fibroblasts and the
inhibition of tumor metastasis.
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3.2 Introduction
Breast cancer is the most common cancer among women with 1 in 8 women
developing it and is the second most common cause of cancer deaths for women [79].
The stage of cancer progression present at the time of diagnosis is a critical determining
factor for both the prognosis of the patient and the course of treatment. There is a fiveyear survival rate of 89% for breast cancer as a whole; however, the survival rate for
patients with advanced stage cancer upon diagnosis decreases precipitously [79]. Breast
cancer staging is based upon the size of the primary tumor, lymph node involvement, and
the presence of distant metastasis. The presence of distant metastasis, most commonly to
the lung, brain, and bone for breast cancer patients, is indicative of stage IV progression
and correlates with a poor prognosis [110]. The presence of distant metastases at
diagnosis lowers the five-year survival rate to just 24% [79]. Metastasis and the growth
of these secondary tumors is the most common cause of cancer-related mortality [11].
Metastasis occurs when tumor cells invade through the basement membrane and
extracellular matrix (ECM) surrounding the tumor, intravasate into the nearby blood and
lymphatic vascular systems, circulate throughout the body, extravasate into a secondary
site, and establish a metastatic lesion. Tumor metastasis requires significant interaction
and signaling between tumor cells and the surrounding stroma. The pro-tumorigenic
stromal influence can be so significant that a debate has developed as to whether the first
carcinogenic signal originates in the epithelium, thereby activating the stroma, or in the
stroma, inducing transformation of the epithelium [136]. Thus it is important to examine
both the signaling from the tumor cells to the stroma and signaling from the stroma to the
tumor cells. The stroma of the mammary gland is distributed throughout the adipocytes of

62

the fat pad and is quite heterogeneous, containing blood vessels with pericytes,
endothelial, and smooth muscle cells, inflammatory and immune cells, and fibroblasts.
While most of the fibroblasts present in the normal mammary gland are quiescent,
cytokines and growth factors present in the tumor microenvironment recruit and activate
the nearby fibroblasts. Although normal fibroblasts can be transformed into cancerassociated fibroblasts (CAFs) through the actions of platelet derived growth factor-α/β,
basic fibroblast growth factor, and interleukin-6, by far the most common method of
activation is through the transforming growth factor (TGF)-β signaling pathway [181,
182]. TGF-β is secreted by both tumor cells and fibroblasts as an inactive homodimer and
bound through chaperone proteins to the ECM. Upon integrin-mediated deformation or
matrix metalloproteinase (MMP) degradation of the ECM, TGF-β is released [183]. The
affinity of TGF-β for its receptors, TGF-β receptor I/II, is greatly enhanced through
interaction with connective tissue growth factor (CTGF) [12]. Upon binding, TGF-β
activates the Smad signaling cascade and transcription of Smad-responsive genes,
including CTGF. In the initial stages of tumor development, activated fibroblasts are antitumorigenic, inhibiting the growth of the tumor via gap junctions connecting the
fibroblasts to each other [144]. As the tumor grows, TGF-β increases reactive oxygen
species production within the fibroblasts, which is thought to be responsible for the
inhibition of the gap junctions [184]. With the loss of the gap junctions, the fibroblasts
become pro-tumorigenic and are classified as CAFs [145]. The activation of CAFs is not
reversible, and, unlike fibroblasts activated during non-pathological, wound-healing
processes, CAFs do not respond to apoptotic signals, resulting in a stable population of
constitutively activated fibroblasts creating a highly fibrotic, desmoplastic tumor
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microenvironment [182, 185]. This increased presence of CAFs within the tumor is
correlated with increased tumor size, metastasis, and poor prognosis [9, 10].
Once activated, CAFs begin remodeling and stiffening the tumor ECM by
decreasing production and degradation of the collagen IV found in normal mammary
basal lamina and increasing the secretion of collagens I and III, fibronectin, and tenascinC [141]. CAFs also produce lysyl oxidase which increases the covalent bonds within
collagen, further stiffening the ECM [147]. This desmoplastic ECM provides a better
substrate for tumor cell migration [150]. However, CAFs exert a direct influence on
tumor cell metastasis as well. Increased CAF production of TGF-β and CTGF
independently increases tumor cell migration [153, 186]. Tumor cells, in turn, stimulate
increased CAF production of MMPs and collagen [187]. Increased MMP production and
contractility allow CAFs to generate protease- and force- mediated tracks in the ECM,
allowing the invading tumor cells to follow behind [150, 151]. Once in the vasculature,
CAFs protect the tumor cells from cell death. By metastasizing with their own primary
site CAFs, the tumor cells are more likely to successfully establish a secondary,
metastatic lesion [152]. It is thought the metastasizing CAFs begin remodeling the
secondary site ECM and creating a pro-tumorigenic environment more quickly than
newly recruited and activated secondary site fibroblasts. Indeed, breast cancer cells coinjected with CAFs exhibit increased tumor growth, angiogenesis, and metastasis as
compared to co-injection with normal fibroblasts [10]. In a separate study, co-injection
with normal fibroblasts overexpressing CTGF also increased tumor growth and
metastasis [188].
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In CAFs, activation of GPER increases production of CTGF, thereby increasing
the proliferation and migration of both CAFs and breast cancer cells in vitro [13, 153].
This role in fibroblasts may account for the high GPER expression correlated with
increased breast cancer metastasis [14, 189], since GPER activation inhibits breast cancer
cell migration, an important step in the metastatic process (Figure 2.6). However, in a
separate study, loss of GPER expression correlated with increased breast cancer
metastasis [129]. It is important to note that in all of these studies, the expression of
GPER was assessed in the tumor cells, not in the surrounding stroma. Thus it is possible
that differences in GPER stromal expression may account for the variances in these
studies. The ability of GPER to increase CTGF, a known fibroblast activator, combined
with the pro-metastatic effect of CAFs, suggests a role for GPER in the transformation of
normal mammary fibroblasts into CAFs, resulting in the increased tumor cell migration
and metastasis associated with high GPER expression.
This study demonstrates GPER activation leads to increased normal mammary
fibroblast activation and proliferation in vitro in an EGFR-ERK-dependent manner.
However, GPER fibroblast activation did not result in increased migration as anticipated,
but inhibited fibroblast migration in vitro. This inhibition was consistent in vivo as the
loss of GPER expression in fibroblasts leads to increased tumor metastasis and larger
metastatic lesions without increased primary tumor size. This increased metastasis was
not a result of altered ECM, as GPER did not affect collagen production either in vitro or
in vivo. Thus, GPER stimulation likely leads to the activation of normal fibroblasts while
inhibiting full transformation into CAFs, resulting in anti-metastatic activity similar to
that of activated normal fibroblasts present in the early stages of tumor growth [144,
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145]. This is the first study to demonstrate a role for GPER in both the activation of
normal fibroblasts and the inhibition of tumor metastasis.

3.3 Methods
3.3.1 Cell lines and reagents. PyMT breast cancer cells, a clonal immortalized,
tumorigenic cell line, were previously generated in the lab from the mammary tumors of
a 7wk FVB/N-Tg(MMTV-PyVT)634Mul/J (MMTV-PyMT) transgenic mouse, that
overexpresses the polyoma middle T antigen (PyMT) under the control of the mouse
mammary tumor virus (MMTV) promoter [167]. PyMT cells were maintained in
epithelial cell medium (DMEM/F-12 supplemented with 5% fetal bovine serum (FBS),
10μg/mL

insulin,

0.5μg/mL

hydrocortisone,

10ng/mL

EGF

and

1%

penicillin/streptomyocin (P/S)). Cells were cultured in a humidified atmosphere
containing 5% CO2 at 37oC. Dulbecco’s Modified Eagle Medium (DMEM)/F12, phenol
red-free DMEM/F12, E2, FBS, NGS, insulin, and hydrocortisone were from Sigma. EGF
and P/S were from Invitrogen. G-1 and G36 were synthesized as described [53] and
provided by Dr. Jeffrey Arterburn (New Mexico State University). EGFR inhibitor
Tyrphostin AG1478, Src inhibitor PP2, and MEK inhibitor U0126 were from
Calbiochem.
3.3.2 Mice. FVB/N-Tg(MMTV-PyVT)634Mul/J (MMTV-PyMT) mice were purchased
from The Jackson Laboratory (Bar Harbor, ME). Previously described GPER KO mice
were provided by Jan Rosenbaum (Proctor & Gamble, Cincinnati, OH) [190]. GPER KO
mice were backcrossed 10 generations onto FVB/NJ mice. FVB GPER KO mice were
intercrossed with MMTV-PyMT mice to produce GPER wild type (WT) or knock out
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(KO) MMTV-PyMT mice. Animals were housed at the animal research facility at the
University of New Mexico Health Sciences Center. They were maintained under a
controlled temperature of 22–23°C with a 12hr light, 12hr dark cycle and fed a normal
chow ad libitum. All procedures were approved and carried out in accordance with
institutional protocols.
3.3.3 Primary mammary fibroblast isolation and activation. To isolate normal
primary mammary fibroblasts, mammary glands from 10 week-old FVB GPER WT or
KO female mice were resected. Tissue was minced and dissociated in DMEM/F12
medium containing 3mg/ml collagenase A (Roche) and 250U/ml hyaluronidase (Sigma)
for 3hr at 37°C with gentle rocking. Dissociated cells were strained through a 500μm
sterile nitex mesh filter. Filtered cells were centrifuged at 48g for 3min at 4°C to remove
the large epithelial cell clusters and debris. The supernatant was transferred to a clean
tube and centrifuged at 200g for 2min at 4°C to remove the remaining epithelial cells and
hematopoietic cells. The supernatant was again transferred to a clean tube and
centrifuged at 500g for 5min at 4°C. The supernatant was discarded, and the fibroblast
pellet was washed in DMEM/F12 media and centrifuged at 500g for 5min at 4°C twice.
Isolated fibroblasts were then either plated in full fibroblast media (DMEM/F12, 10%
FBS, and 1% P/S) or stored in liquid nitrogen in 90% FBS + 10% dimethylsulfoxide
(DMSO). Cells were confirmed as fibroblasts by expression of fibroblast marker
vimentin and absence epithelial marker cytokeratin-18.
For optimal fibroblast activation, FVB GPER WT or KO fibroblasts were seeded
at low confluency (3 x 103 cells/well) in 24-well plate and placed in fibroblast starvation
media (phenol red-free DMEM/F12, 0.5% dextran-charcoal-stripped FBS (c.s. FBS), 1%
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P/S) for 24hr. Cells were then treated in starvation media with DMSO vehicle control, E2
(100nM), G-1 (100nM), or TGF-β (10ng/mL) for 72hr. For inhibitor studies, G36
(500nM), U0126 (250nM), AG1478 (10μM), or PP2 (10nM) were added simultaneously
with treatment. Primary fibroblasts were discarded after 10 passages.
3.3.4 Immunostaining analysis. For cell-based immunostaining, primary FVB GPER
WT or KO normal fibroblasts were cultured on 12mm acid-washed, lysine coated, glass
coverslips and fixed with 4% paraformaldehyde for 20min at 20oC. The cells were
permeabilized with cold methanol for 10min on ice and blocked with 5% normal goat
serum (NGS) diluted in phosphate-buffered saline (PBS) for 15min at 20oC. Cells were
stained with primary antibody diluted in 5% NGS + PBS 1hr at 20oC in a humidified
chamber followed by detection with secondary antibody for 1hr at 20oC. Coverslips were
mounted on slides with Vectashield mounting medium with 4',6-diamidino-2phenylindole (DAPI) (Vector Laboratories). Three random fields from each coverslip
were imaged with a Zeiss 200M Axiovert microscope using MetaMorph software.
Fluorescence intensity was quantitated using ImageJ software (National Institute of
Health). Briefly, the total fluorescence intensity for each image was measured. For
background subtraction, the fluorescence intensity for three random background
selections was divided by the pixel area of the background selections and multiplied by
the total pixel area of the image to determine the image background intensity. The image
background intensity was subtracted from the total fluorescence intensity to determine
the adjusted intensity. This was then divided by the number of cells in the image (as
analyzed by nuclear staining) to determine the intensity per cell. Each sample was then
normalized to sham for a final relative intensity per cell.
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For tissue-based immunostaining, 5μm tissue sections were deparaffinized,
rehydrated, permeabilized in PBS + 0.1% Triton X-100, and blocked in 3% NGS diluted
in PBS + 0.1% Tween-20 (PBS-T). Microwave antigen retrieval was performed in 0.1 M
sodium citrate (pH 6). The tissue was stained with primary antibody diluted in 3% NGS +
PBS-T overnight at 4oC in a humidified chamber followed by detection with secondary
antibody for 1hr at 20oC. Coverslips were mounted on slides with Vectashield mounting
medium with DAPI (Vector Laboratories). At least three random fields from each sample
were imaged with a Zeiss 200M Axiovert microscope using MetaMorph software.
Primary antibodies used were rabbit anti-Ki-67 (Thermo Fisher), mouse antismooth

muscle actin (Abcam), rabbit

anti-phospho-p44/42

MAPK (ERK1/2)

(Thr202/Tyr204) and rabbit anti-p44/42 MAPK (ERK1/2) (Cell Signal), rabbit antiCTGF and rabbit anti-collagen I (Novus Biologicals), and rabbit anti-collagen IV (Nterminal) (Sigma). Secondary antibodies were anti-rabbit and anti-mouse IgG antibodies
conjugated to Alexa 488 or Alexa 555 (Molecular Probes).
3.3.5 Transwell migration assay. Primary GPER WT or KO normal mammary
fibroblasts were placed in starvation media described above for 24hr and pretreated for
72 hours in starvation media with DMSO vehicle control, E2 (100nM), G-1 (100nM), or
TGF-β (10ng/mL). Cells were resuspended and seeded into 8μm pore size Transwell
inserts (Costar) in a 24-well plate at 1.5 x 104 cells/well. Starvation media containing
treatment was added to both the upper and lower chamber and 10% c.s. FBS was added
to the lower chamber as a chemoattractant. After 24h of incubation at 37oC, non-migrated
cells were removed from the upper side of the membrane with cotton swabs, and the cells
on the lower surface of the membrane were fixed in cold methanol on ice for 10min.
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Membranes were mounted with Vectashield mounting medium with DAPI (Vector
Laboratories). Five random fields from each membrane were imaged with a Zeiss 200M
Axiovert microscope using MetaMorph software. The total number of cells for each
membrane were counted and normalized to the vehicle control.
For the co-culture migration assays, GPER WT or KO fibroblasts were seeded
into 24-well plates, placed in fibroblast starvation media for 24hr, and pretreated with
DMSO vehicle control, E2 (100nM), G-1 (100nM), or TGF-β (10ng/mL) for 72hr. The
cells were then thoroughly washed in PBS to remove all treatment. PyMT cells
previously placed in PyMT starvation media (phenol red-free DMEM/F-12 supplemented
with 10μg/mL insulin, 0.5μg/mL hydrocortisone, and 1% P/S) for 24hr were resuspended
in fibroblast starvation media and seeded into 8μm pore size Transwell inserts (Costar)
at 2 x 104 cells/well. The lower chamber of the wells contained the 72hr treated GPER
WT or KO fibroblasts in plain fibroblast starvation media (Figure 3.7 A). PyMT cells
were allowed to migrate for 24hr.
3.3.6 Mammary fat pad clearance and tumor transplantation. The inguinal (#4)
mammary fat pads of 3 week-old FVB GPER WT female mice were cleared of
endogenous epithelium as previously described [95, 96]. On the ventral side of the
mouse, an inverse Y incision was made, and the skin was gently separate from the
peritoneum. The mammary tissue proximal to the fat pad lymph node was removed.
Saline was added to the cavity to prevent fibrotic adhesions, and the skin incision was
closed using steel tissue clips (EZ CLIPS, Stoelting). The mice were given one week to
heal, and the incision was reopened. For mice receiving 25% fibroblasts, 225,000 PYMT
GPER WT tumor cells and 75,000 fibroblasts of indicated genotype were resuspended in
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30μl of DMEM/F12 media and injected into each cleared mammary fat pad. For mice
receiving 50% fibroblasts, 150,000 PYMT GPER WT tumor cells and 150,000
fibroblasts of indicated genotype were injected. Tumor controls of 225,000 (25%) or
150,000 (50%) PYMT GPER WT tumor cells without exogenous fibroblasts were
injected. The skin incision was closed using steel tissue clips. The tumors were allowed
to grow for 6 weeks before resection. Lungs were insufflated with 4% PFA to preserve
architecture. All tissue was fixed overnight in 4% PFA and paraffin embedded.
3.3.7 Heidenhain’s AZAN Trichrome staining. Trichrome stain was performed as
previously described [191]. Five μm tissue sections were deparaffinized, rehydrated, and
placed in 60oC azocarmine solution in water bath for 1hr. Slides were washed, placed in
aniline-alcohol and acetic-alcohol for 1min each, followed by 5% phosphotungstic acid
for 30min. After 1hr in Heidenhain’s blue-orange, slides were rinsed in acidified water,
dehydrated, and mounted using Permount mounting medium (Thermo Fisher).
3.3.8 Histological analysis of lung metastasis. Three, 5μm lung sections separated by at
least 100μm were deparaffinized, rehydrated, and stained with hematoxylin and eosin
(H&E). A metastatic tumor focus present in the lung parenchyma is defined as a tightly
clustered group of 10 or more hematoxylin-positive cells with minimal eosin-stained
stroma. Total metastatic foci were counted in the three lung sections. The area of each
metastatic lesion was determined using ImageJ software (National Institute of Health).
3.3.9 Statistics. Statistical analysis was performed using GraphPad Prism version 4.03.
Comparisons of results between two treatment groups were determined using two-tailed
student’s t-test. Comparisons of results between multiple treatment groups were
determined using a one-way Analysis of Variance (ANOVA) followed by a Bonferroni
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correction for multiple comparisons as a post-hoc test. For both methods of analysis, data
represents the mean ± SEM of three or more separate experiments. P-values less than
0.05 were considered to be significant.

3.4 Results
3.4.1 GPER activates normal mammary fibroblasts
Characterization of the in vitro effects of GPER activation within isolated human
mammary CAFs has recently begun [153]. However, the role of GPER in promoting the
activation of fibroblasts into CAFs remains unexamined. Therefore, primary normal
mammary fibroblasts were isolated from FVB/NJ GPER wild-type (FVB WT) and
FVB/NJ GPER knockout (FVB KO) mice. Following E2 and growth factor starvation for
24hr, the fibroblasts were treated for 72hr with the GPER-selective agonist, G-1, and
expression of smooth muscle actin (SMA) was measured. Among the initial stages of
fibroblast activation is the upregulation of SMA, as the fibroblasts begin to exhibit a
myofibroblast phenotype. Accordingly, the expression of SMA is the most commonly
accepted marker of fibroblast activation [192]. Activation of GPER in FVB WT
fibroblasts resulted in a two-fold increase of SMA expression as compared to sham
(Figure 3.1 A, B). This activation was completely inhibited by the addition of the GPERselective antagonist, G36 (Figure 3.1 C), indicating GPER contributes to the activation of
normal fibroblasts. Additionally, neither E2 nor G-1 treatment induced SMA expression,
and thus fibroblast activation, in FVB KO fibroblasts (Figure 3.1 D).
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Figure 3.1 GPER activation promotes normal mammary fibroblasts activation.
A) FVB WT fibroblasts were treated for 72hr with G-1, immunostained for SMA
(green) and counterstained with DAPI nuclear stain (blue). B) FVB WT SMA
expression was quantitated as described in methods. C) FVB WT fibroblasts treated
72hr with G-1, G36, or combined. SMA was quantitated as described. D) FVB KO
fibroblasts treated 72hr with E2 or G-1. SMA was quantitated as described. *p < .05
compared to sham.
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3.4.2 GPER increases fibroblast proliferation
Because GPER is known to increase CAF proliferation [153], a proliferation
assay was performed on FVB WT and KO normal fibroblasts. As in the activation assay,
the fibroblasts were starved for 24hr and treated with E2 or G-1 for 72hr. The cells were
immunostained for Ki-67 and proliferating cells were quantitated. G-1, but not E2,
resulted in significantly increased fibroblast proliferation as compared to sham (Figure
3.2 A). This proliferation was abrogated by the addition of G36 (Figure 3.2 B) and absent
in FVB KO fibroblasts (Figure 3.2 D). The lack of increased proliferation following
treatment with E2 could be due to an inhibitory effect by either ERα or ERβ as E2
activates all three estrogen receptors present in the fibroblasts. A balance between ERαinduced proliferation and ERβ-dependent inhibition would also account for the absence
of any change in proliferation in FVB WT fibroblasts treated with a combination of E2
and GPER-selective antagonist, G36 (Figure 3.2 C). This is consistent with the role of
ERβ as an inhibitor of ERα-induced proliferation [76].
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Figure 3.2 GPER activation increases fibroblast proliferation. Fibroblasts were
treated for 72hr and immunostained to detect the proliferation marker Ki-67. Data
is expressed as the percentage of total fibroblasts positive for Ki-67. A) FVB WT
fibroblasts treated with E2 or G-1. B) FVB WT fibroblasts treated with G-1, G36,
or combined. C) FVB WT fibroblasts treated with E2, G36, or combined. D) FVB
KO fibroblasts treated with E2 or G-1. *p < .05 compared to sham. #p < .05
compared to G-1.
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3.4.3 GPER activates fibroblasts through MAPK
The pathway by which GPER induced fibroblast activation was next examined.
GPER signaling most commonly occurs through MMP cleavage of heparin-bound EGF
(HB-EGF) resulting in the transactivation of EGFR and the MAPK cascade, specifically
mediated through ERK-1/2-dependent signaling (Figure 1.4). Activation of EGFR and
MAPK is known to result in fibroblast activation. To determine if GPER-dependent
activation occurs through this pathway, FVB WT fibroblasts were activated by E2 and G1 as described above, and phospho-ERK (p-ERK) was examined by immunodetection.
While not statistically significant, GPER activation by both G-1 and E2 trends towards
increased p-ERK within the fibroblasts (Figure 3.3 A). Furthermore, treatment with the
MEK, and thus ERK, inhibitor U0126 abolishes GPER-dependent fibroblast activation,
as determined by SMA expression (Figure 3.3 B). Additionally, EGFR inhibition by
AG1478 also abolishes fibroblast activation (Figure 3.3 C), indicating the transactivation
of EGFR and ERK are required for GPER-induced fibroblast activation.
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Figure 3.3 GPER activation promotes fibroblasts activation through MAPK. A)
FVB WT fibroblasts treated 72hr with E2 or G-1 and immunostained for p-ERK
(green) and counterstained with DAPI nuclear stain (blue). B, C) FVB WT fibroblasts
treated 72hr with G-1 and B) U0126, an ERK inhibitor, or C) AG1478, an EGFR
inhibitor, and immunostained for SMA (green) and DAPI (blue). All images
quantitated as described in Methods. *p < .05 compared to sham. #p < .05 compared
to G-1.
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3.4.4 GPER activation of fibroblasts is Src-independent
The ability of GPER to signal through Src within fibroblasts not only leads to
possible MMP-independent activation of EGFR and ERK, it may also lead to increased
fibroblast migration through the phosphorylation of FAK and turnover of focal adhesions.
To determine if Src is involved in GPER-induced signaling in normal fibroblasts, FVB
WT fibroblasts were treated with G-1 and PP2, a Src inhibitor, for 72hr. Inhibition of Src
did not significantly decrease fibroblast activation, as determined by SMA expression
(Figure 3.4), indicating Src is not necessary for GPER-dependent fibroblast activation.
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Figure 3.4 GPER activation induced fibroblast activation is Src-independent.
FVB WT fibroblasts treated 72hr with G-1 and PP2, a Src inhibitor, and
immunostained for SMA (green) and counterstained with DAPI nuclear stain (blue).
All images quantitated as described in Methods. *p < .05 compared to sham.
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3.4.5 GPER does not stimulate CTGF production in normal fibroblasts
CTGF has a prominent role in the activation of normal fibroblasts and migration
of CAFs [188]. Production of CTGF within CAFs is significantly increased by the
activation of GPER [153]. To determine the effect of GPER activation on CTGF
production in normal mammary fibroblasts, FVB WT fibroblasts were treated with E2 or
G-1 for 72hr, and CTGF was measured by immunostaining. GPER activation did not
alter CTGF expression, as compared to sham, in FVB WT fibroblasts (Figure 3.5 A).
Combination treatment with G36 in FVB WT fibroblasts (Figure 3.5 B) or treatment with
E2 or G-1 in FVB KO fibroblasts also exhibited no effect on CTGF production (Figure
3.5 C). Although GPER reportedly increases CTGF production in both tumor cells and
CAFs thereby inducing proliferation and migration [13, 153], it does not increase CTGF
production in normal mammary fibroblasts.
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Figure 3.5 GPER activation does not stimulate CTGF production in normal
fibroblasts. Fibroblasts were treated 72hr, immunostained for CTGF (green), and
counterstained with DAPI nuclear stain (blue). A) FVB WT fibroblasts treated with E2
or G-1. B) FVB WT fibroblasts treated with E2, G-1, G36, or combined. C) FVB KO
fibroblasts treated with E2 or G-1. All images quantitated as described in Methods.
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3.4.6 GPER inhibits normal fibroblast migration
While GPER increases SMA expression and proliferation within normal
mammary fibroblasts, full transformation into CAFs also requires an increase in motility.
To test migration in GPER-activated fibroblasts, a Transwell migration assay was
performed. FVB WT fibroblasts were starved for 24hr and pretreated with G-1 for 72hr
for full activation prior to being seeded into Transwell chambers and allowed to
migrate for 24hr. Activation with G-1 resulted in significant inhibition of normal
fibroblast migration as compared to sham (Figure 3.6 A). FVB WT fibroblasts treated
with G-1 and G36 together (Figure 3.6 B) or FVB KO fibroblasts treated with G-1
exhibited no migration inhibition (Figure 3.6 C). Instead, FVB WT fibroblasts treated
with either G36 alone or in combination with G-1 increased migration, as compared to
sham, indicating GPER expression results in inhibition of a basal level of migration.
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Figure 3.6 GPER activation inhibits normal fibroblast migration. Transwell
migration assays were performed on fibroblasts pretreated for 72h and allowed to
migrate for 24hr. Cells migrating through the membrane were counted and normalized
to sham-treated controls. A) FVB WT fibroblasts treated with G-1. B) FVB WT
fibroblasts treated with G-1, G36, or combined. C) FVB KO fibroblasts treated with
G-1. *p < .05 compared to sham.
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3.4.7 GPER mediates fibroblast-induced tumor cell migration
Tumor cell activation of CAFs results in CAF-induced tumor cell migration and
the development of a positive feedback loop [153, 186, 187]. To determine if GPERactivated normal fibroblasts have any effect on breast cancer cell migration, a co-culture
Transwell migration assay was performed. FVB WT fibroblasts were treated with E2 or
G-1 for 72hr. After removal of treatment, untreated PyMT GPER WT (PyMT WT) breast
cancer cells were placed in Transwell inserts in the fibroblast-containing wells and
allowed to migrate for 24hr (Figure 3.7 A). While not statistically significant, there is a
pronounced trend toward increased breast cancer cell migration in response to GPERactivated fibroblasts (Figure 3.7 B). Additionally, the G-1 treated FVB WT fibroblasts
exhibit significantly increased proliferation, as compared to sham (Figure 3.7 C), and a
nearly two-fold increase over proliferation without exposure to breast cancer cells (Figure
3.2 A). This data suggests once more that the signaling between tumor cells and
fibroblasts in the microenvironment increases the pro-metastatic abilities of both cell
types and activation of GPER appears to enhance this signaling.
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Figure 3.7 GPER activation mediates tumor cell-induced fibroblast proliferation.
A) Transwell co-culture migration assays setup. GPER WT PyMT cells were seeded
in top chamber with 72hr pretreated fibroblasts on bottom. Cells migrating through the
membrane after 24hr were counted and normalized to sham-treated controls. B)
Migration of PyMT cells exposed to E2 or G-1 pretreated FVB WT fibroblasts. C) E2
or G-1 pretreated FVB WT fibroblasts exposed to migrating PyMT cells were
immunostained to detect the proliferation marker Ki-67. Data is expressed as the
percentage of total fibroblasts positive for Ki-67. *p < .05 compared to sham.
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3.4.8 GPER fibroblast expression does not affect tumor size
To determine the effects of GPER expression in fibroblasts on tumor growth in
vivo, the orthotopic transplant mouse model was employed. Prior to pubertal
development, the epithelial ductal structure is restricted to the proximal end of the
mammary fat pad and can be surgically removed. Tumor cells can then be orthotopically
transplanted into the cleared fat pad, allowing growth in a physiologically relevant
environment free of any endogenous epithelial growth [95, 96]. In this study, PyMT WT
breast cancer cells were mixed with either FVB WT or KO normal fibroblasts and coinjected into the cleared inguinal fat pad of FVB WT mice to determine the effect of
GPER fibroblast expression on tumor growth after 6 weeks. The tumor cells and
fibroblasts were mixed at a low, 25% fibroblast ratio and a higher, 50% fibroblast ratio.
By having two fibroblast concentrations, it can be determined if the concentration of
fibroblasts present within the tumor impacts tumor growth and metastasis in a dosedependent manner. Additionally, at the 50% fibroblast ratio, any effects of endogenous
FVB WT fibroblasts present in the recipient fat pad will be overwhelmed. There were no
significant differences in tumor weight in either 25% or 50% FVB WT or KO fibroblastco-injected tumors, as compared to control tumors injected with no exogenous fibroblasts
(Figure 3.8 A, B), indicating GPER expression in fibroblasts does not impact tumor
growth and size.
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Figure 3.8 GPER expression in fibroblasts does not affect tumor size. PyMT WT
breast cancer cells were mixed with either FVB WT or FVB KO normal fibroblasts at
A) 25% or B) 50% fibroblast ratio and co-injected into the cleared inguinal fat pad of
FVB WT mice. Control tumors (None) did not contain any exogenous fibroblasts.
After 6 weeks, tumors were weighed and normalized to the body weight of the mouse.
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3.4.9 Loss of GPER expression in the mammary fat pad increases ECM production
One of the primary, pro-metastatic functions of CAFs is the conversion of the
normal mammary ECM into the much stiffer, desmoplastic tumor ECM, primarily
through increased production and crosslinking of collagen I and degradation of collagen
IV [141, 147, 182]. To determine if GPER expression within the fat pad alters tumor
desmoplasia, PyMT WT breast cancer cells were orthotopically transplanted without
exogenous fibroblasts into the cleared inguinal fat pad of FVB WT or KO mice. Injecting
tumors into an FVB GPER KO mouse allows for analysis of the role of GPER in all of
the cells present in the cleared mammary fat pad, including blood vessels, immune cells,
and fibroblasts, all of which may influence ECM production. The tumors were sectioned,
and a Heidenhain’s AZAN trichrome stain (trichrome) was performed, staining the ECM
components collagen and laminin, as well as cartilage and mucus, within the tumors blue
[191]. PyMT WT tumors grown in FVB KO fat pads display an increased amount of
ECM as compared to tumors grown in an FVB WT microenvironment (Figure 3.9),
indicating GPER expression in the tumor microenvironment inhibits ECM production.
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Figure 3.9 Loss of GPER expression in the mammary fat pad increases ECM
production. PyMT WT cells were orthotopically transplanted into the cleared inguinal
fat pad of FVB WT or KO mice. Tumors were sectioned and a Heidenhain’s AZAN
trichrome stain was performed, staining the ECM within the tumors blue. Three
images from three different mice shown for both FVB WT and KO mice.
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3.4.10 GPER does not affect fibroblast collagen production
Since fibroblasts are the primary stromal cell responsible for ECM production, it
was determined if this increased ECM production was a result of GPER loss in
fibroblasts specifically, rather than a loss of GPER in all of the cells localized within the
stroma as examined above. PyMT WT tumor cells and either FVB WT or KO normal
fibroblasts were orthotopically transplanted into FVB WT mice, and the tumors were
trichrome-stained to determine ECM content. While the amount of ECM was quite varied
within each tumor, as well as between tumors, there were no apparent differences in
ECM production between tumors containing FVB WT or KO fibroblasts (Figure 3.10 A).
Because trichrome stains all types of collagen blue, the specific effect of GPER fibroblast
expression on the production of collagen I, the predominant ECM component produced
by CAFs, was determined by immunostaining. While the levels of collagen I within the
tumors was quite heterogeneous overall, there appeared to be no difference in collagen I
levels comparing tumors co-injected with FVB WT or KO fibroblasts (Figure 3.10 B).
While CAFs are the predominant source of collagen I within a tumor, collagen produced
by endothelial cells was also detected within blood vessel walls [193]. To quantitate the
collagen I produced specifically by GPER-activated fibroblasts in the absence of tumor
cells, Western blot analysis was performed for collagen I and IV production by FVB WT
(Figure 3.11 A) or FVB KO fibroblasts (Figure 3.11 B) treated in vitro with either E2 or
G-1 for 72hr. Consistent with the in vivo results, there was no significant difference in
collagen I or IV secretion by GPER-activated FVB WT or KO fibroblasts in vitro.
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Figure 3.10 GPER expression does not affect fibroblast collagen production in
vivo. PyMT WT cells were mixed with FVB WT or KO fibroblasts at a 50% ratio
and co-injected into FVB WT mice. After 6 weeks, tumors were A) trichrome
stained and B) immunostained for collagen I (green) and counterstained with DAPI
(blue).
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Figure 3.11 GPER activation does not affect fibroblast collagen production in
vitro. A) FVB WT or B) FVB KO fibroblasts treated for 72hr with E2 or G-1.
Collagen I and IV secreted into the media were analyzed by Western blot. Data was
normalized to sham.
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3.4.11 Loss of GPER increases lung metastasis
Although GPER activates normal mammary fibroblasts (Figure 3.1), this
activation resulted in decreased fibroblast migration in vitro (Figure 3.6). Since migratory
and co-metastasizing CAFs promote breast cancer metastasis [150, 152], GPER-induced
migration inhibition would suggest a possible role for GPER in the inhibition of tumor
metastasis. However, these experiments in the present study were done in vitro with
fibroblasts in isolation, without any exposure to tumor cells. As previously discussed, the
cross-talk between fibroblasts and tumor cells is critical. To determine the functional
effect of GPER expression in normal mammary fibroblasts in a physiologically relevant
environment on tumor metastasis, the lungs of the FVB WT or KO fibroblast and PyMT
WT tumor bearing mice were removed and examined for metastatic lesions by H&E
staining. Orthotopically transplanted PyMT tumor cells consistently metastasize to the
lungs [194]. Tumors transplanted with 50% FVB WT or KO fibroblasts did not exhibit
any significant differences in the number of metastatic lesions present in the lungs, as
compared to tumors transplanted without exogenous fibroblasts (Figure 3.12 A).
However, PyMT WT tumors containing 50% FVB KO fibroblasts developed
significantly more metastatic lesions within the lungs than either control tumors or FVB
WT fibroblast tumors (Figure 3.12 B). To further determine the extent of metastasis, each
metastatic lesion was measured. Both 25% and 50% FVB KO fibroblasts significantly
increased the area of each metastatic lesion (Figure 3.12 C), as well as increased total
metastatic area within the lung tissue (Figure 3.12 D). This indicates the loss of GPER
within fibroblasts fosters a pro-metastatic environment in which metastatic tumors exhibit
increased growth.
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Figure 3.12 Loss of GPER increases lung metastasis. PyMT WT breast cancer cells
were mixed with either FVB WT or FVB KO normal fibroblasts at A) 25% or B) 50%
fibroblast ratio and co-injected into the cleared inguinal fat pad of FVB WT mice.
Control tumors (none) did not contain any exogenous fibroblasts. After 6 weeks,
lungs were H&E stained and metastatic foci were counted. C) Area of each metastatic
lesion was measured. D) Total metastatic area was measured for each mouse. Area is
measured in relative units. *p < .05 compared to none.
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3.5 Discussion
Important research has been conducted recently characterizing the protumorigenic role of activated cancer-associated fibroblasts in tumor growth and
metastasis. The increased presence of CAFs within the tumor is correlated with increased
tumor size, metastasis, and poor prognosis [9, 10]. Since metastasis is the primary cause
of cancer-related death, it is critical to understand the mechanisms by which normal
fibroblasts become activated and transformed into CAFs. Because this activation
primarily occurs through CTGF-enhanced TGF-β signaling and GPER significantly
increases CTGF production in CAFs and breast cancer cells [13, 153], the role of GPER
in the activation of normal mammary fibroblasts was examined.
Upon activation, fibroblasts begin producing SMA to increase motility and
contractility and adopt a myofibroblast phenotype. Activation of GPER in primary,
normal, mammary fibroblasts by the synthetic ligand, G-1, results in the de novo
expression of SMA indicative of an activated fibroblast (Figure 3.1 A, B). This fibroblast
activation was accompanied by increased GPER-dependent proliferation (Figure 3.2 A)
and required the activation of EGFR and ERK signaling (Figure 3.3). However, this
activation did not require Src activity (Figure 3.4). In the classical GPER signaling
pathway, E2 binding to GPER results in Gβγ subunit activation of Src. Src then either
directly transactivates the EGFR or activates MMPs to cleave HB-EGF, thus activating
the EGFR (Figure 1.4). While no known studies have demonstrated Src-independent
GPER activation of EGFR, recent studies have shown direct interaction of GPCRs with
both EGFR and IGF-1R through the Gβγ subunit [132, 195]. Additionally, IGF-1Rdependent proliferation in both MCF-7 breast cancer cells and Ishikawa endometrial
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cancer cells requires GPER [4]. Thus, GPER may transactivate EGFR either directly or
through interaction with IGF-1R, rather than in a Src-dependent manner, thereby
increasing fibroblast proliferation.
In CAFs and breast cancer cells, GPER stimulation of ERK and its downstream
AP-1 element results in increased production of CTGF [13, 153]. However, in normal
fibroblasts activated by GPER, as defined by SMA production, CTGF was not
upregulated (Figure 3.6). GPER-dependent normal fibroblast activation also decreased
migration (Figure 3.4 A), and inhibition of GPER increased migration 50% compared to
control (Figure 3.4 B). Though unexpected, this migration inhibition is consistent with a
recent study in breast cancer cells demonstrating GPER-dependent ERK phosphorylation
of Smad inhibits the TGF-β migration signal [196]. This study is supported by increasing
evidence of MAPK inhibition of TGF-β signaling [197-199]. The regulation of the
interaction between these two fundamental cellular pathways is complex and still poorly
understood. When fibroblasts are exposed to breast cancer cells, there is increased TGF-β
produced by both cell types [186]. Thus, when GPER-activated fibroblasts and PyMT
breast cancer cells are co-cultured, GPER-dependent fibroblast proliferation is increased
(Figure 3.7 C), and there is a trend toward increased stimulation of breast cancer cell
migration (Figure 3.7 B). This suggests a role for GPER in mediating the fibroblasttumor signaling.
To further examine the effects of GPER expression in fibroblasts on the paracrine
signaling between tumor cells and fibroblasts, tumors were grown orthotopically in vivo
in the presence of fibroblasts either expressing or lacking GPER. The absence of GPER
expression in fibroblasts resulted in an increased number and size of metastatic lesions

96

(Figure 3.12). While GPER expression in the stroma as a whole, including blood vessels,
immune cells, and fibroblasts, decreased ECM production (Figure 3.9), the loss of GPER
in fibroblasts alone did not increase ECM levels, particularly collagen (Figure 3.10, 11).
Although the fibroblasts were normal when transplanted, TGF-β produced by the nearby
tumor cells should have transformed them into CAFs [181, 182, 200]. However, this in
vivo activation could not be assessed within this study. Consistent with the in vitro
studies, it is possible GPER-mediated MAPK signaling within the fibroblasts dampens
the activating TGF-β stimulus, thus inhibiting the ability of the fibroblasts to support
metastasis. Additionally, TGF-β signaling increases reactive oxygen species production,
inhibiting the gap junctions present in activated normal fibroblasts [184]. Fibroblasts
maintaining gap junction communication exhibit an anti-metastatic phenotype [144].
When GPER expression in fibroblasts is eliminated, TGF-β signaling would no longer be
suppressed by the GPER-mediated MAPK signaling, thereby completing the positive
feedback loop and inducing the further transformation of activated fibroblasts into CAFs.
This transformation result in increased metastasis of both the CAFs and tumor cells.
Thus, GPER stimulation likely leads to the activation of normal fibroblasts while
inhibiting full transformation into CAFs, resulting in anti-metastatic activity similar to
that of activated normal fibroblasts present in the early stages of tumor growth [144,
145].
Tumor cells metastasizing with primary site fibroblasts exhibit less cell death,
from both apoptosis and immune surveillance, within the blood and are able to establish a
greater number of metastatic lesions [152]. In addition, these lesions grow larger than
those depleted of primary site CAFs [152], similar to the effect seen in tumors containing
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fibroblasts lacking GPER. This is the first study to demonstrate a role for GPER in both
the activation of normal fibroblasts in vitro and the inhibition of tumor metastasis in vivo,
possibly through the inhibition of TGF-β activation.

98

CHAPTER 4

ESTROGEN RECEPTOR EFFECTS IN THE MOUSE ENDOMETRIUM
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4.1 Abstract
The classical responses to estrogen activity within the uterus, proliferation and
water imbibition, are traditionally attributed to ERα activation resulting in both increased
gene transcription and rapid signaling. However, with the discovery of GPER, a new
estrogen receptor capable of inducing proliferation, this assumption required reexamination. This study began examining the individual E2-dependent responses of ERα
and GPER, as well as the independent roles of ERα transcriptional regulation and rapid
signaling through the use of selective ligands. GPER-dependent proliferation within the
lumenal epithelial cells was demonstrated through the GPER-selective agonist, G-1. This
proliferation was abolished by the GPER-selective antagonist, G15. However, GPER is
not involved in imbibition as G-1 was unable to induce a response and G15 did not
inhibit the E2-induced imbibition. To determine the mechanism by which ERα induces
imbibition and proliferation, AB-1, an ERα and ERβ selective ligand that activates
genomic responses but not rapid signaling, was used. Because ERβ does not increase
endometrial proliferation or imbibition [201], AB-1-induced proliferation or imbibition
can be reasonably assigned to ERα. Both proliferation and imbibition can occur
independently of ERα rapid signaling. However, rapid signaling appears to be required
for complete imbibition as AB-1-stimulated gene transcription only induced ~60% of the
E2-induced imbibition.

4.2 Introduction
In the adult, non-pregnant, pre-menopausal female, the menstrual cycle induced
by cyclic ovarian 17β-estradiol (E2) production results in a biphasic uterine physiology.
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The follicular, or proliferative, phase is characterized by proliferation of epithelial cells in
the innermost functional layer of the endometrium as E2 levels increase to a maximal
level at ovulation. During the secretory phase, progesterone (P4) levels increase, inducing
the differentiation and proliferation of stromal cells to transform the endometrium into a
receptive environment for implantation. In the absence of implantation, the functional
layer is shed as P4 levels decrease [64]. The E2-dependent proliferation and edema
observed during the proliferative phase are well described and accepted as classical
responses within the uterus [73, 74]. However, the mechanisms by which they occur are
still being characterized.
E2 activates ERα and induces proliferation within the lumenal epithelial cells of
the endometrium [32]. This increased proliferation likely occurs through both the rapid
signaling and genomic responses of ERα. Upon estrogen binding, ERα dimerizes and
binds either directly to an estrogen response element (ERE) within the promoter region of
a target gene or to the binding site of an associated cofactor, such as the AP-1 or SP-1
transcription factors (Figure 1.3) [40, 41]. ERα is able to either promote or repress
transcription of the target gene, depending on the cofactors recruited. Several
proliferation genes are upregulated, including myc and cyclin D1, primary regulators of
the cell cycle [202]. While this increase has been attributed solely to the transcriptional
abilities of ERα, evidence in breast cancer cells indicates this transcription may also be
dependent upon ERα stimulating rapid signaling through cAMP and protein kinase A
(PKA) [202]. ERα rapid signaling responses may also increase epithelial cell
proliferation through activation of the MAPK and PI3K signaling cascades [43].
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E2 is also responsible for the increased fluid accumulation within the
endometrium during the proliferative phase of the menstrual cycle [203]. ERα increases
uterine blood vessel permeability through increased production of vascular endothelial
growth factor (VEGF) and nitric oxide (NO). The compromised endothelial barrier is
unable to restrict protein movement, resulting in increased serum proteins entering the
uterine stroma [204-206]. This protein influx creates an osmotic imbalance, leading to
increased water within the interstitial spaces in the stroma. The water is then passively
and actively transported across the lumenal epithelial cells and into the lumenal space,
where it will be excreted as uterine lumenal fluid. E2 increases the expression of the
water channel aquaporins (AQP) through the activation of ERα, thereby increasing the
lumenal fluid [207]. The process of E2-induced water imbibition can be inhibited by
actinomyocin D, an inhibitor of protein translation and transcription, indicating
transcriptional regulation and de novo protein synthesis is critical for ERα activity [204].
However, as in ERα-induced proliferation, it is unknown if ERα rapid signaling is
required for this gene transcription.
The discovery of the estrogen receptor GPER has required reanalysis of
estrogenic responses previously attributed to ERα. E2 stimulated proliferation in both
ERα positive Ishikawa and ERα negative HEC1A endometrial cancer cell lines was
abolished following GPER knockdown [87]. This proliferation was induced through the
activation of the MAPK cascade, consistent with the known GPER signaling pathway
(Figure 1.4). Additionally, although tamoxifen (TAM) acted as an ERα antagonist within
Ishikawa cells, treatment with TAM resulted in increased cell growth, consistent with
TAM serving as GPER agonist [50, 87]. Proliferation stimulated by TAM activation of
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GPER may explain why women treated with TAM are at an increased risk of developing
endometrial cancer [81]. However, the role of GPER in proliferation of normal
endometrium in vivo has yet to be examined.
In this study, selective ligands for GPER, ERα, and ERβ were used to determine
the role of each receptor in the classical uterine estrogen responses, proliferation and
water imbibition. The GPER-selective agonist, G-1, demonstrated GPER-dependent
proliferation within the lumenal epithelial cells. This proliferation was abolished by the
GPER-selective antagonist, G15. However, GPER is not involved in imbibition. To
determine the mechanism by which ERα induces imbibition and proliferation, AB-1, an
ERα and ERβ selective ligand that activates genomic responses but not rapid signaling,
was used. Because ERβ does not increase endometrial proliferation or imbibition [201],
AB-1-induced proliferation or imbibition can be reasonably assigned to ERα. Both
proliferation and imbibition can occur independently of ERα rapid signaling. However,
rapid signaling appears to be required for complete imbibition as AB-1-stimulated gene
transcription only induced ~60% of the E2-induced imbibition.

4.3 Methods
4.3.1 Mice. Ovariectomized, 10 week-old C57Bl/6J female mice were purchased from
Harlan Laboratories. Animals were housed at the animal research facility at the
University of New Mexico Health Sciences Center. They were maintained under a
controlled temperature of 22–23°C with a 12hr light, 12hr dark cycle and fed normal
chow ad libitum. All procedures were approved and carried out in accordance with
institutional protocols.
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4.3.2 AB-1 uterine analysis. C57Bl/6 female mice were ovariectomized at 10 weeks of
age and allowed to rest and acclimate to their environment for 10-14 days. This time also
allows any residual ovarian E2 circulating throughout the body to be eliminated. Mice
were subcutaneously injected once daily for three days with 100μL of sham control, E2
(2ng or 10ng) (Sigma) or AB-1 (2μg, 10μg, or 90.9μg) (ChemDiv). All compounds were
dissolved in ethanol. Injections were 10% ethanol containing treatment and 90% aqueous
vehicle (0.9% (w/v) NaCl with 0.1% (w/v) albumin and 0.1% (v/v) Tween-20). Ethanol
alone (10μL) was added to 90μL aqueous vehicle as control. 24hr after final injection,
each mouse was weighed, and the uterus was removed, weighed, fixed in 4% PFA, and
embedded in paraffin.
4.3.3 GPER uterine analysis. C57Bl/6 female mice were ovariectomized at 10 weeks of
age and allowed to rest and acclimate to their environment for 10-14 days. This time also
allows any residual ovarian E2 circulating throughout the body to be eliminated. Mice
were subcutaneously injected with 100μL of sham control, E2 (200ng), G-1 (40ng,
200ng, or 1000ng) (Dr. Jeffrey Arterburn, New Mexico State University), G15 (272ng,
900ng, or 2725ng) (Dr. Jeffrey Arterburn, New Mexico State University), or G15 (272ng,
900ng, or 2725ng) combined with E2 (200ng) or G-1 (200ng). All compounds were
dissolved in ethanol. Injections were 10% ethanol containing treatment and 90% aqueous
vehicle as described above. 18hr after injection, each mouse was weighed, and the uterus
was removed, weighed, fixed in 4% PFA, and embedded in paraffin.
4.3.4 Immunostaining analysis. For proliferation analysis, 5μm uterine tissue sections
were deparaffinized, rehydrated, permeabilized in PBS + 0.1% Triton X-100, and
blocked in 3% normal goat serum (NGS) diluted in PBS + 0.1% Tween-20 (PBS-T).
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Microwave antigen retrieval was performed in 0.1 M sodium citrate (pH 6). The tissue
was stained with rabbit anti-Ki-67 (Thermo Fisher) primary antibody diluted in 3% NGS
+ PBS-T overnight at 4oC in a humidified chamber followed by detection with anti-rabbit
secondary antibody conjugated to Alexa 488 (Molecular Probes) for 1hr at 20oC.
Coverslips were mounted on slides with Vectashield mounting medium containing 4',6diamidino-2-phenylindole (DAPI) (Vector Laboratories). Three random fields from each

sample were imaged with a Zeiss 200M Axiovert microscope using MetaMorph
software.
4.3.5 Statistics. Statistical analysis was performed using GraphPad Prism version 4.03.
Comparisons of results were determined using two-tailed student’s t-test. Data represents
the mean ± SEM of three or more separate experiments. P-values less than 0.05 were
considered to be significant.

4.4 Results
4.4.1 ERα transcriptionally regulates water imbibition and epithelial proliferation
ERα activity occurs through both genomic and rapid signaling. Often the
individual roles of these two mechanisms are blurred, as it is difficult to separate
genomic- and rapid signaling-induced activity in vivo. AB-1 is a selective agonist for
both ERα and ERβ [62, 63, 208], demonstrating negligible ability to bind GPER (Dr. Eric
Prossnitz, unpublished observations). AB-1 binding to ERα and ERβ increases gene
transcription [63, 208] with an EC50 of 15nM, compared to 0.1nM for E2. However, AB1 antagonizes ERα-induced calcium mobilization and PI3K activation rapid signaling
(Dr. Eric Prossnitz, unpublished observations). Thus the use of AB-1 allows for the
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separation of ER transcriptional activity from rapid signaling. While ERβ is expressed in
the uterus, ERα expression and activity are predominant in the mature, premenopausal,
non-pregnant uterus [68, 69]. Additionally, ERβ activation does not result in increased
proliferation [76, 201]. Therefore, the effects of AB-1 on water imbibition and
proliferation can be reasonably assigned to ERα. To examine the ability of ERα
transcriptional activity to induce water imbibition in the mouse uterus, sexually mature
female mice were ovariectomized to remove the predominant source of premenopausal
E2. The mice were injected once daily for three days with either E2 or AB-1. The uteri
were removed and weighed, as increased uterine weight relative to body weight is a
measure of imbibition. Both E2 and AB-1 significantly increased uterine wet weight, and
thus imbibition, in a dose dependent manner, as compared to sham control (Figure 4.1 A).
However, AB-1 was not able to achieve the same level of water uptake as E2, inducing
~60% of the E2-induced imbibition. This diminished response is not attributable to the
affinities of AB-1 (EC50 = 15nM) and E2 (EC50 = 0.1nM) for ERα, as the highest AB-1
dose (90.9μg) was nearly 10,000-fold higher than the necessary E2 dose (10ng), far
exceeding the differences in affinities. This suggests a role for ERα-dependent rapid
signaling in the enhancement of transcription responsible for water uptake.
To determine the role of ERα-mediated transcription on lumenal epithelial cell
proliferation, Ki-67 positive lumenal epithelial cells were quantitated. Both AB-1 and E2
significantly increased lumenal epithelial cell proliferation by five-fold as compared to
the sham control (Figure 4.1 B). In contrast to uterine water imbibition, AB-1 and E2
induced proliferation equally, indicating ERα-mediated transcriptional activity is
sufficient for ERα to fully stimulate proliferation.
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A

B

Figure 4.1 ERα transcriptionally regulates water imbibition and epithelial cell

proliferation. Mice were injected once daily for three days with E2 or AB-1. A) The
uterus was weighed and normalized to body weight. B) Uteri were immunostained to
detect the proliferation marker Ki-67. Data is expressed as the percentage of total
lumenal epithelial cells positive for Ki-67. *p < .05 compared to sham.
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4.4.2 GPER does not regulate water imbibition
To determine the role of GPER in E2-stimulated water imbibition within the
uterus, sexually mature female mice were ovariectomized and injected with G-1, a GPER
selective agonist. After 18hr, the uteri were removed and weighed. Activation of GPER
by G-1 did not result in water imbibition at any dose (Figure 4.2 A). To confirm GPER
activation by the endogenous ligand, E2, did not impact imbibition, E2 or E2 in
combination with G15 was injected, and wet weight was measured after 18hr. As a
GPER-selective antagonist, G15 should block any E2 activation of GPER. Thus any E2induced effect exhibited following treatment with G15 can be solely attributed to ERα or
ERβ. Treatment with E2 resulted in significantly increased weight, and thus water uptake,
and treatment with G15 was unable to inhibit this effect (Figure 4.2 B), confirming GPER
is not necessary for E2-induced water imbibition.
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A

B

Figure 4.2 GPER does not regulate water imbibition. Mice were injected once with

A) G-1 or B) E2, G15, or E2 and G15 combined. After 18hr, the uterus of each
mouse was weighed and normalized to body weight. *p < .05 compared to sham.
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4.4.3 GPER increases uterine epithelial cell proliferation
Since GPER increases proliferation of endometrial cancer cells in vitro [50, 87,
209], sexually mature ovariectomized mice were treated with either G-1 for 18hr, and
proliferation was quantitated. At each dose, G-1 significantly increased lumenal epithelial
cell proliferation compared to sham control, and treatment with G15 abrogated the G-1induced response (Figure 4.3 A). To confirm the role of GPER in E2-stimulated
proliferation, mice were treated with E2 or E2 and G15. E2 significantly increased
proliferation as compared to the control, and G15 partially inhibited the E2-induced
proliferation (Figure 4.3 B), indicating E2 stimulates uterine proliferation through both
ERα and GPER.
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A

B

Figure 4.3 GPER increases uterine epithelial cell proliferation. Mice were
injected once with A) G-1, G15, or G-1 and G15 combined or B) E2 or E2 and G15
combined. After 18hr, the uteri were immunostained to detect the proliferation
marker Ki-67. Data is expressed as the percentage of total lumenal epithelial cells
positive for Ki-67. *p < .05 compared to sham. **p < .05 compared to G-1 or E2.
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4.5 Discussion
The classical markers of estrogen activity within the uterus, proliferation and
water imbibition, are traditionally attributed to ERα signaling. However, with the
discovery of GPER, a new estrogen receptor capable of inducing proliferation, this
assumption required re-examination. This study began assessing the individual E2dependent responses of ERα and GPER, as well as the roles of ERα transcription
regulation and rapid signaling through the use of selective ligands.
E2 activation of ERα induces cellular effects through both the regulation of
transcription and the activation of rapid signaling pathways. Because they often occur
concomitantly, it has been difficult to specifically assign ERα-dependent effects to either
of these two mechanisms in vivo. The development of the ERα- and ERβ-selective ligand,
AB-1, and the demonstration of its ability to activate transcriptional activity while
antagonizing rapid signaling allows for mechanistic distinction of these two responses.
While ERβ is expressed in the uterus, ERα expression and activity are predominant in the
mature, premenopausal, non-pregnant uterus [68, 69]. Additionally, ERβ activation does
not result in increased proliferation [76, 201]. Therefore, the effects of AB-1 on water
imbibition and proliferation can be reasonably assigned to ERα. Through AB-1, it was
determined ERα transcriptional activation is responsible for both increased water uptake
and proliferation within the endometrium (Figure 4.1 A). However, maximal water
uptake appears to require rapid signaling as well, since excess AB-1 was unable to induce
a response of the same amplitude as E2-induced imbibition. This rapid signaling is most
likely production of NO through ERα-dependent MAPK phosphorylation and activation
of endothelial nitric oxide synthase (eNOS). ERα-induced NO production and
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vasodilation is an important step in the imbibition process and is independent of de novo
protein synthesis [210]. The increased ERα-dependent transcription and de novo
synthesis of VEGF and the water channel AQP stimulate water uptake, though this
response is incomplete in the absence of NO production. Although E2 does not increase
water imbibition through GPER alone (Figure 4.2), GPER may be able to stimulate rapid
signaling necessary to elicit a full E2 water imbibition response. This could be
determined by treating mice with AB-1 to induce ERα-dependent transcription combined
with G-1 to stimulate GPER-dependent rapid signaling.
While the water imbibition response does not require GPER activity, E2-induced
proliferation does require GPER activation to mediate a complete response and can be
partially inhibited through treatment with a GPER antagonist (Figure 4.3). In a recent
study, E2-stimulated xenograft endometrial tumor growth was almost completely
inhibited following treatment with G36, a second-generation GPER-selective antagonist
[209]. One of the most intriguing implications of GPER-induced endometrial
proliferation lies in the ability of tamoxifen (TAM) to serve as a GPER agonist. Women
treated with TAM for breast cancer are at an increased risk of developing endometrial
cancer [81]. While ERα is agonized by TAM in the uterus, ERα expression is inversely
correlated with markers of poor outcome in endometrial cancer, such as aggressive
histological subtypes, adnexal spread, myometrial invasion, de-differentiation and
recurrence [88, 90]. High GPER expression levels are inversely correlated with ERα
expression, and positively correlate with markers of poor prognosis, such as high grade,
advanced stage, cervical involvement, and aggressive histology, as well as an overall
lower survival rate. This positive correlation becomes more pronounced with high-grade
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III/IV tumors [70]. Likewise, high endometrial GPER expression has been significantly
correlated with the development of TAM-induced endometrial pathology as well as with
increased progression rate of endometrial polyps or hyperplasia [127].
Aside from these correlative studies, direct evidence demonstrates TAM
stimulated proliferation and invasion of endometrial cancer cells occurs in a GPERdependent manner [91]. TAM activation of GPER and downstream MAPK results in
increased production of pro-migratory MMP-2 and -9 and IL-6, a cytokine associated
with aggressive endometrial cancer and a shorter survival period [211]. Blocking GPER
signaling abrogates the pro-tumorigenic effects of TAM [91], presenting intriguing
treatment possibilities. To further explore this role in tumor growth and metastasis, mice
with endometrial tumors could be treated with TAM to inhibit ERα in combination with
G15 or G36 to inhibit GPER, thus inhibiting all of the known E2 receptors. Additionally,
adjuvant treatment with the GPER inhibitors G15 or G36 may minimize the malignant
endometrial effects of TAM treatment of breast cancer, thereby increasing patient
survival.
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CHAPTER 5

CONCLUSIONS AND FUTURE DIRECTIONS

115

5.1 Summary and Future Directions
This study provides evidence for the contribution of GPER to the migration of
both normal breast epithelial and breast tumor cells and to the activation and function of
fibroblasts in the breast tumor microenvironment. Proliferation and migration are two of
the most critical steps within both normal mammary development and breast cancer
progression. The role of E2 in increasing proliferation in normal and tumor cells through
both ERα and GPER is well characterized [1-3]. ERα is critical for the coordinated
proliferation and migration necessary for proper ductal elongation and morphogenesis
within the breast during puberty [94]. However, ERα seems to have an inhibitory effect
on breast cancer metastasis, as expression has been inversely correlated with metastasis
[128].
While the role of GPER in the migration of normal breast epithelial cells remains
largely unexamined, GPER activation increases breast cancer cell migration in vitro,
primarily through inducing the fibroblast and breast cancer cell production of CTGF [13].
However, GPER may also inhibit breast cancer cell migration [53]. It is not currently
known under what conditions GPER promotes or inhibits migration. In a retrospective
study, GPER expression in breast cancer samples directly correlated with increased tumor
size and metastasis [14]. However, in a separate study, loss of GPER expression
correlated with increased breast cancer metastasis [129]. It is important to note that in all
of these studies, the expression of GPER was assessed in the tumor cells, not in the
surrounding stroma.
In addition to clinical correlation studies, the role of GPER in breast cancer
metastasis has been directly examined using the mouse mammary tumor virus-polyoma
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middle T antigen (PyMT) mouse model of breast cancer, which spontaneously develops
mammary tumors in a manner similar to the development of human tumors [167, 212].
The hormonal dependence of PyMT tumors has been demonstrated as tumors allowed to
develop in the absence of ovarian E2 or treated with tamoxifen (TAM) exhibit a much
smaller tumor size. Treatment with the GPER-selective antagonist G36 does not affect
tumor size or grade; however, G36 does inhibit E2-induced lung metastasis (Nicole
Marjon, unpublished observations). Similarly, PyMT GPER knockout (PyMT KO) mice
exhibit significantly fewer metastatic lesions than control PyMT GPER WT (PyMT WT)
mice. PyMT WT tumor cells orthotopically transplanted into the non-tumorigenic
mammary fat pad of FVB KO recipient mice also develop significantly fewer metastatic
lesions as compared to FVB WT recipient mice (Nicole Marjon, unpublished
observations). Taken together, these data suggest GPER within the tumor
microenvironment is a critical component of E2-induced breast cancer metastasis.
Metastasis is responsible for the vast majority of cancer-related deaths and is a
complex process involving not only the tumor cells, but also a wide variety of cell types
present within the tumor microenvironment [11]. These include the vascular system, with
both established and newly formed blood vessels, and the immune system, with both
adaptive T cells and innate macrophages and natural killer cells. The loss of GPER
expression affects both of these systems through increased vasoconstriction and a proinflammatory environment [213-216]. The microenvironment may also impact tumor
growth and metastasis through metabolic regulation [217]. GPER KO mice exhibit
metabolic dysregulation resulting in increased obesity compared to GPER WT mice
[216]. Although the effect of GPER within these systems has been individually studied,
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the role of GPER in these systems has not yet been examined in the context of the tumor
microenvironment.
In

addition

to

the

vascular

and

immune

cells

present

within

the

microenvironment, a principal cell type aiding tumor metastasis through both direct and
indirect interaction are cancer-associated fibroblasts (CAFs). Normal mammary
fibroblasts are recruited by the tumor cells and transformed into CAFs primarily through
the actions of TGF-β produced by the tumor cells [145, 182]. The increased presence of
CAFs within the tumor microenvironment is correlated with increased tumor size and
metastasis [9, 10]. Once activated, CAFs begin remodeling and stiffening the tumor ECM
by decreasing production of collagen IV found in normal mammary basal lamina and
increasing the secretion of MMPs, collagens I and III, fibronectin, and tenascin-C [141].
This stiffer, fibrotic ECM, referred to as desmoplastic ECM, provides a better substrate
for tumor cell migration [150]. CAFs also directly aid in tumor cell metastasis by leading
tumor cells out of the primary tumor site, protecting them from apoptosis and immune
surveillance within the blood stream, and increasing their ability to successfully establish
a secondary tumor site [10, 150-152]. GPER-dependent production of CTGF within
CAFs increases both fibroblast and breast cancer cell proliferation and migration [13,
153]. Since CTGF is also a potent fibroblast activator, this study examined the role of
GPER in the activation and function of normal mammary fibroblasts.
Because cancer development, growth, and metastasis are often the result of
deregulated physiological processes, the role of GPER in normal breast epithelial cell
migration was first examined. Using methods to analyze both collective and individual
cell migration, GPER was demonstrated to increase collective migration without
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impacting individual migration. In breast cancer cells, however, a different role for GPER
was observed as individual migration was inhibited. It is possible the differences
observed between the MCF10A and PyMT cell lines may be due to the fundamental
differences between human, non-tumorigenic, breast epithelial cells and mouse breast
cancer cells. To determine which of these differences, if any, impact the ability of GPER
to affect cell migration, collective and individual migration assays should be performed
on human breast cancer cells and normal mouse mammary epithelial cells.
GPER-dependent inhibition of PyMT breast cancer cell migration may also be
due to the presence of ERβ. While MCF10A cells only express GPER, PyMT cells
express all three known estrogen receptors. In addition to its role in inhibiting
proliferation, ERβ has recently been shown to inhibit migration of breast cancer cells as
well [179, 180]. This inhibition can occur in a ligand-independent manner through the
phosphorylation of ERβ S105 by ERK1/2. Of note, phosphorylated ERβ is unable to
inhibit proliferation in a ligand-independent manner [179]. Thus it is possible GPERselective activation by G-1 in PyMT cells may transactivate ERβ through ERK1/2
resulting in migration inhibition. If ERβ is inhibiting GPER-stimulated migration,
knocking down ERβ in PyMT tumor cells should result in increased migration.
Additionally, transfecting ERβ into MCF10A cells may inhibit GPER-induced migration,
thus demonstrating a role for ERβ in regulating GPER-dependent migration in normal
breast epithelial cells as well.
The role of ERβ S105 phosphorylation inhibiting migration may also explain the
lack of migration inhibition observed by ECIS measurement. Because PyMT breast
cancer cells do not exhibit the contact inhibition present in epithelial cells and
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phosphorylated ERβ is unable to inhibit proliferation in a ligand-independent manner
[179], the PyMT cells may have filled the wound over the electrode through GPERinduced proliferation. Thus it is important to analyze PyMT breast cancer cell
proliferation in response to GPER activation. Additionally, to confirm the potential
masking effect of GPER-dependent proliferation on migration inhibition, migration of G1 treated PyMT cells in the presence of a proliferation inhibitor should be measured. By
inhibiting proliferation, GPER-induced PyMT migration should increase due to the
absence of opposing MAPK signals.
Although GPER activation in PyMT cells inhibited migration, when exposed to
GPER activated normal fibroblasts, PyMT migration trended toward an increase, though
this increase was not statistically significant. In this experiment, the PyMT cells and
fibroblasts shared media and thus were able to stimulate one another in a paracrine
manner through secreted factors. However, evidence indicates physical interaction
between fibroblasts and cancer cells has a much greater effect on the activation of both
cell types through juxtacrine signaling [150, 186, 218]. It is necessary to determine the
impact of GPER fibroblast activation on the effects of fibroblast-tumor cell contact. The
interaction may stimulate the production of CTGF reported in CAFs treated with G-1.
CTGF production was not stimulated in GPER-activated normal fibroblasts, suggesting
an additional signal, perhaps TGF-β, from the tumor cells is necessary for complete
transformation of GPER-activated normal fibroblasts into CAFs.
It is possible this fibroblast-tumor cell contact may also amplify the statistically
insignificant effects on tumor cell migration observed in co-culture experiments
performed in this study. However, GPER-activated fibroblasts may inhibit the tumor cell

120

migration when in direct contact, similar to the in vivo metastasis model in which coinjection with GPER KO fibroblasts in direct contact with the tumor cells resulted in
more metastatic lesions than GPER WT fibroblasts. To examine this interaction, GPERactivated fibroblasts and PyMT breast cancer cells could be co-cultured on an artificial
basement membrane in an organotypic system as previously described [150]. In this
system, fibroblast-tumor interaction results in measurable invasion into the basement
membrane. From this experiment, it can be determined if direct interaction between
GPER-activated fibroblasts and PyMT breast cancer cells alters the migratory and
invasive abilities of both cell types. If direct interaction with GPER KO fibroblasts
resulted in increased PyMT cancer cell invasiveness, this would provide clues into
possible mechanisms by which GPER in fibroblasts inhibit tumor metastasis in vivo. This
organotypic in vitro experiment also removes the confounding factor of endogenous
GPER WT fibroblast effects present in the GPER KO fibroblast tumors transplanted into
GPER WT mice.
The organotypic model of fibroblast and cancer cell interaction also allows for
better measurement of ECM components produced by the fibroblasts along the invasion
track [150]. While GPER activation of normal fibroblasts alone in vitro did not affect
collagen production, perhaps GPER-activated fibroblast interaction with PyMT breast
cancer cells is necessary for increased collagen I and fibronectin production. Fibroblasttumor cell contact has been demonstrated to significantly increase fibroblast production
of collagen and fibronectin [219]. It is also possible for fibroblasts to alter the ECM
composition through increased production of MMPs. Fibroblasts use MMPs to degrade
the anti-metastatic collagen IV and create tracks for the tumor cells to follow [150, 151,
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187]. GPER increases the proteolytic activity of MMP-2 and -9 as part of the
transactivation of EGFR [49, 220], and a recent in vitro study in ovarian cancer cells
demonstrated GPER activation increased invasiveness through the increased production
of MMP-9 [5]. GPER-dependent fibroblast MMP production may be increased through
direct fibroblast-tumor cell contact [187]. MMP production by GPER-activated
fibroblasts alone or in the presence of PyMT breast cancer cells can be assessed through
gel zymography, the standard method for assessing MMP production [221].
In addition to increasing tumor cell migration and invasion, co-metastasizing
CAFs protect the tumor cells within the blood stream resulting in a greater number of
metastatic lesions [152]. These lesions grow larger than those depleted of primary site
CAFs [152], similar to the effect seen in tumors containing GPER KO fibroblasts in vivo.
A difference in GPER WT and KO fibroblast metastatic ability would be consistent with
the in vitro data demonstrating GPER WT fibroblast activation by G-1 inhibited
fibroblast migration. To determine if GPER KO fibroblasts are metastasizing with the
tumor cells more than GPER WT fibroblasts, GPER KO mice can be crossed with GFP
transgenic mice to produce fluorescently labeled primary mammary fibroblasts with or
without GPER expression. PyMT breast cancer cells and either GFP+ GPER WT or
GFP+ GPER KO fibroblasts can be transplanted into non-GFP expressing FVB recipient
mice and allowed to grow. The metastatic lesions in the lungs can be examined for the
presence of GFP+ cells. Because neither the recipient mouse nor the transplanted tumor
cells express GFP, any GFP+ cell present in the metastatic lung lesion must be a primary
site fibroblast. By quantitating the number of primary site fibroblasts, it can be
determined if GPER expression in fibroblasts inhibits fibroblast metastasis resulting in
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fewer and smaller lesions as observed in this study. If there is determined to be a
difference in the number of GPER WT and KO fibroblasts in the metastatic lesions, it
may be due to inhibition of either migration and invasion necessary for intravasation or
extravasation and establishment of the secondary site [152].
To distinguish between the two metastatic processes of extravasation and
intravasation, mixed PyMT tumor cells and either GFP+ GPER WT or KO fibroblasts
can be inoculated directly into the bloodstream, bypassing intravasation. This approach
allows for selective examination of the role GPER in fibroblasts during extravasation and
the establishment of the secondary tumor site. If GPER inhibits fibroblast-dependent
ECM remodeling, the fibroblasts would be unable to provide the beneficial effects of
metastasizing CAFs within the bloodstream and in establishing a pro-tumorigenic
microenvironment in the secondary tumor site. This would result in fewer, smaller lesions
than those produced by GPER KO fibroblasts as observed in this study. If GPER inhibits
fibroblast-dependent invasion there would be minimal difference in the number and size
of lesions from GPER WT and KO fibroblasts, since this step will be bypassed. It is more
likely, however, that GPER has effects on both invasion and ECM production, and direct
vascular injection would result in a partial increase in metastatic lesion size and number,
as compared to the orthotopic transplant model performed in this study.
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5.2 Overall Conclusions
This study demonstrated alternate roles for GPER in normal and tumor breast
cells through the promotion of normal epithelial cell migration and the inhibition of both
breast cancer cell and normal fibroblast migration in vitro. GPER expression in
fibroblasts also resulted in the partial inhibition of tumor metastasis and secondary tumor
site growth in vivo. The anti-metastatic role of GPER in fibroblasts examined within this
study suggests intriguing therapeutic possibilities. It also presents a possible cause for the
discrepancies in the clinical correlation studies reporting that high GPER tumor
expression is correlated with both increased and decreased metastasis as these reports
only measured GPER expression in the tumor cells [14, 129]. If, as the data presented in
this study suggests, GPER expression in fibroblasts is a key determinant in the metastatic
potential of the tumor, it is critical to begin determining the expression levels of GPER
not just within the tumor cells, but also within the stroma and surrounding fibroblasts for
a more accurate prognosis. This data suggests that a high GPER expression level within
the fibroblasts would indicate a lower likelihood of metastasis, and thus a more favorable
prognosis. By therapeutically targeting the anti-metastatic ability of GPER-expressing
fibroblasts with GPER-selective agonists like G-1, it may be possible to confine a tumor
to the primary location. By reducing distant metastasis, better treatment options,
minimizing the use of systemic chemotherapy and its harmful side effects, would be
available resulting in improved patient survival. However, complications from treatment
with a GPER agonist could arise if the tumor cells express high levels of GPER. Within
tumor cells, GPER increases proliferation and may lead to increased migration [1, 3, 13].
As such, treatment with a GPER agonist would only be advisable when the fibroblasts
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express high levels of GPER and the tumor cells express low levels of GPER. A more
detailed understanding of the interconnected, complex effects GPER has on breast cancer
metastasis through tumor cells, fibroblasts, and many other stromal cells will allow for
better GPER-targeted treatment options to be developed to prevent metastasis and
improve patient survival.
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